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Highlights: 
 
• Different diaryl ureas are designed and synthesized. 
• The antimycobacterial activity has been checked against M. smegmatis (mc2155) and M. 
tuberculosis (mc26030 and H37Rv strains). 
• The EDG and EWG are found to have a preference for the ortho and meta positions of the first 
aromatic ring respectively. 
• The cytotoxicity values are in the range of 92-232 µg/ml. 
• The effective molecules showed selective inhibitory activity on mycolic acid biosynthesis in 14C-
radiolabelled assay. 
• Effective molecules of this series up regulate the expression level of iNOS2, IFN-γ, IL-12 and 
down regulate the level of IL-10 to clear the mycobacterium infection.  
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Abstract: Tuberculosis is a major threat for mankind and the emergence of resistance strain of 
Mycobacterium tuberculosis (Mtb) against first line antibiotics makes it lethal for human 
civilization.  In this study, we have synthesized different diaryl urea derivatives targeting the 
inhibition of mycolic acid biosynthesis. Among the 39 synthesized molecules, compounds  46, 
57, 58 and 86 showed MIC values ≤ 10 µg/ml against H37Rv and mc26030 strains. The best 
molecule with a methyl at ortho position of the first aromatic ring and prenyl group at the meta 
position of the second aromatic ring showed the MIC value of 5.2 µg/ml and 1 µg/ml against 
H37Rv and mc26030 respectively, with mammalian cytotoxicity of 163.4 µg/ml. The effective 
compounds showed selective inhibitory effect on mycolic acid (epoxy mycolate) biosynthesis in 
14C-radiolabelled assay. At the same time these molecules also executed their potent 
immunomodulatory activity by up-regulation of IFN-γ and IL-12 and down-regulation of IL-10. 
 
Key words: Tuberculosis, Diaryl urea, Structure-activity relationship, antimycobacterial activity, 
Cytotoxicity, Mycolic acid, cytokines.  
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1. Introduction: Mycobacterium genus of pathogenic species are responsible for a 
variety of infectious diseases, e. g., tuberculosis and leprosy which are caused by M. 
tuberculosis (Mtb) and M. leprae respectively.1 Altogether, infections caused by this 
group of species are primarily accountable for millions of death annually among different 
life forms. In particular, according to the World Health Organization (WHO) report 
(2015), in the year of 2014, 1.5 million deaths were caused by tuberculosis (TB) along 
with an estimated 9.6 million new TB incidences.2 Among the 9.6 million new TB cases 
12% people were found to be co-infected with HIV, which brings new challenges for 
conventional treatment methods that is mostly dependent on antibiotics. The AIDS 
patients co-infected with TB, are needed to be completely cure from TB in order to avoid 
the interaction of first line antibiotics (e. g., Rifampacin and Isoniazid) with anti-HIV 
drugs such as protease inhibitors.3,4 However, the high tolerance level of Mtb towards first 
line antibiotics along with their ability to survive in the dormant (non-replicating) state is 
a major concern to provide a complete cure against TB. 
 There are several targets for the antituberculosis drugs; arguably, the most 
important one is the cell wall biosynthesis. Early in 1970, Isoxyl or thiocarlide was used 
as an antituberculosis drug which inhibits the synthesis of mycolic and oleic acids. The 
∆9-stearoyl desaturase was identified as the primary target of isoxyl.5-7 However, the use 
of isoxyl was restricted due to its interference with mammalian monoamine oxidase.8 It is 
also reported that isoxyl get converted to an active form by the monooxygenase EthA.9 
During this bioactivation process, the thiourea gets converted to the urea one.10 Therefore, 
different urea derivatives can represent as a suitable scaffold for the development of 
potent antitubercular and immunomodulatory molecule. Several attempts are also made to 
achieve this particular purpose.11-15 
 Most TB infections are commenced through the respiratory route. They first get 
implanted in the alveoli to form the Ghon complex.16,17 During the progression of TB they 
thrive inside the host alveolar macrophages and impaired the host protective response. 
The virulent Mtb stain (H37Rv) modulates the host immune response in their favour by 
up-regulation of the anti-inflammatory cytokines e. g., IL-10, arginase and down-
regulation of the proinflammatory cytokines, e. g., iNOS, IL-12, IFN-γ.18 Therefore, 
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designing of immunomodulatory molecules also has a great possibility to cure against 
Mtb by re-educating the host immune response. 
 In this work, we have synthesized several unsymmetrical diaryl ureas to 
understand the relation between activity and cytotoxicity despite knowing the fact that the 
minimum inhibitory concentration (MIC) value of the urea analogue of isoxyl is ~100 
times higher than isoxyl itself.19 The key reasons for substituting the thiourea moiety with 
its bioisostere urea20-22 are (i) to reduce the possibility of interaction with unspecified 
target through the sulphur atom and (ii) to find out a cost effective synthetic method for 
the low-income TB patients.  
 The first aromatic ring of this series of molecules is substituted with different 
substitutions having disparate inductive (I) and mesomaric (M) effects, whereas, the 
second aromatic ring is substituted with three different aliphatic chains at the meta and 
para positions (Fig 1). Different combinations of the substitution on both aromatic rings 
have a great scope to correlate their efficacy with cytotoxicity.  
N
H
N
H
S OO
Isoxyl
Symmetrical molecule
N
H
N
H
O
R1 OR2
Unsymmetrical molecule
1st ring 2nd ring
Substituted with 
I & M groups
Substituted with 
aliphatic chain
 
Figure 1: Site of modification at two aromatic rings. 
 
The synthesized molecules were first tested for their direct killing effect on Mtb and M. 
Smagmatis, followed by the evaluation of their ramification on fatty acid and mycolic acid 
biosynthesis by the 14C-radio-labeled assay and it was done with the selected compounds from 
each different effective prototypes. Finally, the best three molecules of this entire series were 
investigated for their possible immunomodulatory effect upon proinflammatory and anti-
inflammatory cytokines by measuring their mRNA expression level with the help of RT-PCR. 
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2. Results and Discussion: 
2.1 Synthesis of Urea analogues:  
 In an effort to trounce the involvement of mammalian monoamine oxidase, we have 
prepared   several diaryl ureas. A diverse set of molecules have been synthesized in order to 
determine the relationship between antitubercular efficiency with its different substitutions. To 
obtain this specific goal we had introduced several functionalities (with inductive and/or 
mesomeric effect) in the first aromatic ring, whereas, second aromatic was substituted with three 
different aliphatic substituents.     
 To introduce +I, -I, -I & -M and –I & +M effect in the first aromatic ring at its 
ortho/meta/para position six groups methyl (+I), trifluoromethyl (-I), nitro, halides, hydroxyl 
and amino (-I & -M) were primarily selected. However, the hydroxyl substitution was ruled out 
because of its potential participation in Mitsunobu reaction. For the amino substitution although 
we were able to prepare the monomer using high dilution method but the resulting diarylurea 
was found to yield benzimidazole (as confirmed by the NMR) during the HBr mediated 
demethylation step. Again, BBr3 mediated demethylation for this system was found sluggish in 
nature (data not shown). Therefore, we were only able to synthesize compounds having methyl, 
trifluoromethyl, m-nitro and halides groups at three different positions of the first aromatic ring. 
 The diaryl ureas 1 - 20 were synthesized by the reaction of their corresponding amines 
(un-substituted and substituted) with 3- and 4-Methoxyphenyl isocyanate in dichloromethane 
(DCM) (Scheme 1)23. Aforesaid method was quite successfully utilized for the m-Nitroaniline (-I 
& -M), however, for o-Nitroaniline and p-Nitroaniline we opted for the other alternative. The 
strong –I and –M effect of the nitro group is presumed to be responsible for diminishing the 
nucleophilicity of the amine. The demethylation steps were accomplished with HBr (50% in 
acetic acid) at 70 °C. Thereafter, the three different aliphatic alcohols were coupled with their 
respective phenol counterpart via Mitsunobu coupling reaction24 to yield final compounds 41 - 
72. 
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NH2
R1 +
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OCH3
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O
R1
CompR1
H; m-NO2
o-CH3; m-CH3; p-CH3
o-F; m-F; p-F
o-Cl; m-Cl; p-Cl
o-Br; m-Br; p-Br
o-CF3; m-CF3; p-CF3
R1 R2
1           H            m-OCH3
2           H             p-OCH3
3        m-NO2       m-OCH3
4        m-NO2        p-OCH3
5        o-CH3        m-OCH3
6        o-CH3         p-OCH3
7       m-CH3         m-OCH3
8        p-CH3        m-OCH3
9           o-F          m-OCH3
10         m-F         m-OCH3
Comp R1 R2
11        p-F           m-OCH3
12        o-Cl          m-OCH3
13       m-Cl          m-OCH3
14        p-Cl          m-OCH3
15        o-Br          m-OCH3
16       m-Br          m-OCH3
17       p-Br           m-OCH3
18       o-CF3        m-OCH3
19       m-CF3       m-OCH3
20       p-CF3        m-OCH3
24: R1 = H; 25: R1 = NO2(m); 26: R1 = CH3(o)    
27: R1 = CH3(m); 28: R1 =  CH3(p); 29: R1 =  F(o)          
30: R1 = F(m); 31: R1 =  F(p); 32: R1 = Cl(o)          
33: R1 = Cl(m); 34: R1 = Cl(p); 35: R1 = Br(o)          
36: R1 = Br(m);  37: R1 = Br(p); 38: R1 = CF3(o)        
39: R1 = CF3(m); 40: R1 = CF3(p)
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OH
21: R1 = H; 22: R1 = NO2(m)
23: R1 = CH3(o)
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O
41: R1 = H; 42: R1 = NO2(m); 43: R1 = CH3(o)
3
44: R1 = H; 45: R1 = NO2(m); 46: R1 = CH3(o)
47: R1 = H; 48: R1 = NO2(m); 49: R1 = CH3(o)
N
H
N
H
O
R1
O
N
H
N
H
O
R1
O
N
H
N
H
O
R1
O 3
50: R1 = H; 51: R1 = NO2(m); 52: R1 = CH3(o)
53: R1 = H; 54: R1 = NO2(m); 55: R1 = CH3(o)
56: R1 = H; 57: R1 = NO2(m); 58: R1 = CH3(o)    
59: R1 = CH3(m); 60: R1 = CH3(p); 61: R1 =  F(o); 
62: R1 = F(m); 63: R1 =  F(p); 64: R1 = Cl(o)
65: R1 = Cl(m); 66: R1 = Cl(p); 67: R1 = Br(o)
68: R1 = Br(m); 69: R1 = Br(p); 70: R1 = CF3(o) 
71: R1 = CF3(m); 72: R1 = CF3(p);
(i)
(ii)
(iii)
(iii)
Allyl 
alcohol
Allyl 
alcohol
1-Butanol
1-Butanol
Prenol
Prenol
 
Scheme 1: Reagents and conditions: (i) DCM (dry), 3-5 h, rt; (ii) HBr/AcOH, 10 h, 70 °C; (iii) DIAD/TPP in THF, 
6-8 h, rt. 
 The previous scheme did not work well (yield<5%) because of the poor reactivity of o 
and p-Nitroaniline and m-Cyanoaniline towards the isocyanates. To overcome the reactivity issue 
for the groups with -I & -M effect, we used o and p-Nitrophenyl isocyanate and m-Cyanophenyl 
isocyanate and reacted them with 3- and 4-Anisidine to obtain 73 – 76. The use of anisidine 
increased the nucleophilicity of the amine, whereas, presence of nitro and cyano groups 
enhanced the electrophilicity of the isocyante. This combination worked well (yield >75%) and 
made it possible to prepare compounds 78 – 80 and 84 – 86 (Scheme 2).   
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+
N
H
N
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O
R2R1
Comp R1 R2
73        o-NO2       m-OCH3
74        p-NO2       m-OCH3
75        m-CN        m-OCH3
76        m-CN        p-OCH3
R1
o-NO2
p-NO2
m-CN
N
H
N
H
O OH
78: R2 = Allyl 
79: R2 = n-Butyl
80: R2 = prenyl
N
H
N
H
O
R1
OH
(ii) or (iii)
CN
77
(iv)
N
H
N
H
O OR2
CN
R2 OH
(iv)
N
H
N
H
O
R1
OPrenol
84: R1 = o-NO2 
85: R1 = p-NO2 
86: R1 = m-CN
(i)
81: R1 = o-NO2 
82: R1 = p-NO2 
83: R1 = m-CN
 
Scheme 2: Reagents and conditions: (i) DCM (dry), 3-5 h, rt; (ii) HBr/AcOH, 10 h, 70 °C; (iii) BBr3 in 
DCM, 10 h, rt; (iii) DIAD/TPP in THF, 6-8 h, rt. 
 
 For the carboxylic acid derivative we started with ethyl 3-aminobenzoate and 3-
Methoxyphenyl isocyanate. The demethylation step was carried out in presence of HBr at 
70 oC followed by the esterification of the carboxylic group (89). The carboxylic group 
was protected again to resist its participation in Mitsunobu reaction. Thereafter, the 
phenolic OH group was coupled with prenyl alcohol under Mitsunobu reaction condition 
followed the de-esterification of the carboxylic group with LiOH (90) (Scheme 3). 
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Scheme 3: Reagents and conditions; (i) DCM (dry), 4 h, rt; (ii) HBr/AcOH, 12 h, 70 °C; (iii) SOCl2/MeOH, reflux 5 
h; (iv) DIAD/TPP in THF, 8 h, rt; (v) LiOH/H2O, 4 h, rt. 
 For all the synthesized molecules, only one aromatic ring of diaryl urea is substituted 
with different groups having altered I and M effect, whereas, the second one bears only an 
aliphatic chain at para and meta positions. To compare the effect of different substituents in first 
aromatic ring, compound 41, 44, 47, 50, 53 and 56 were prepared (Scheme 1), where the first 
aromatic ring is un-substituted but the second aromatic ring is substituted by all the three 
aliphatic chains at the meta and para positions. 
 
2.2 Antimycobacterial activity: 
 The antimycobacterial activities and cytoxicities all 39 compounds are given in Tables 1-
3. The bactericidal activity was determined against M. Smegmatis (mc2155) and two other Mtb 
strains mc26030 (non pathogenic strain) and H37Rv (pathogenic). The Mtb strain mc26030 is 
derived from H37Rv, which is lacking of region of difference 1 (RD1) as well as is an auxotroph 
for pantothenic acid.25 MIC values were determined by three different methods, namely, serial 
dilution method26 (for mc2155), agar plate method27 (for Mtb mc26030) and Microplate Alamer 
Blue assay (MABA)28,29 (for Mtb H37Rv). Mammalian HepG2 cell line was used to determine 
their cytoxicity and the corresponding IC50 values were calculated from their dose response 
curve. Thereafter, the best compounds were taken forward to ascertain their direct effect on 
mycolic and fatty acid biosynthesis by 14C-radiolebelled assay. Finally, their potential 
immunomodulatory activity was tested by measuring different cytokines levels in infected 
peritoneal macrophage to probe an alternative pathway for the clearance of mycobacterium 
species by this series of molecules. 
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Correlation between +I vs -I effect and activity: 
 The first set of compounds 41, 44, 47, 50, 53 and 56 were prepared as a reference 
to correlate the activity of different substituents on the first aromatic ring. Therefore, for 
this set of molecules the first aromatic ring was kept un-substituted and the second 
aromatic ring was substituted with three different aliphatic chains at meta and para 
positions.  This set of molecules showed moderate activity against mc2155, mc26030 and 
H37Rv strains except for compound 47. The MIC values for 47 were found 25 µg/ml, 30 
µg/ml and 43.1 µg/ml respectively against mc2155, mc26030 and H37Rv strains. 
However, for this set of molecules allyl and prenyl substitutions (second aromatic ring) 
showed better effect against H37Rv strain (>75%) compared to n-butyl one (<60%) at 50 
µg/ml concentration. The small discrepancies of the MIC values against mc26030 and 
H37Rv strains can be attributed for the difference in their susceptibility profile and for the 
methods being used to determine the drug efficacy (solid agar plates versus broth 
medium). The cytotoxicity for these molecules was found to vary between 182.4 to 124.1 
µg/ml. Replacement of the thiourea moiety with its bioisostere (urea) showed a promising 
effect in order to decrease their cytotoxicity level compared with isoxyl.13  
 To compare only the role of +I and –I effect, we have prepared another two sets of 
molecules 43, 46, 49, 52, 55, 58, 59 and 60 (with +I effect) and 70 - 72 (with –I effect). Initial 
screening of 43, 46, 49, 52, 55, 58, 59 and 60 on different mycobacterium species showed the 
preference of +I group at ortho and para positions for their better activity, whereas, out of the 
six variants of this set the optimum activity was found for compound 58 with a prenyl group at 
the meta position on the second aromatic ring (Table 1). The MIC values were found 12.5 µg/ml, 
1 µg/ml and 5.2 µg/ml against mc2155, mc26030 and H37Rv strains respectively. This finding 
confirmed us about the preferred position of the prenyl chain for second aromatic ring. After 
optimization of the position and nature of aliphatic chain another two variants 60 and 59 were 
prepared to find out the effect of methyl group at meta and para positions. The MIC values were 
found 32.2 µg/ml and 10.5 µg/ml for 60and 59 respectively against H37Rv strain. The collective 
antimycobacterial activity of 58, 59 and 60 confirmed the perpetuation of the ortho position for 
an +I group. Relative activity of 58 and 60 also provided an indication about the effect of steric 
congestion near the urea bond. Now to validate the above mentioned inference another set of 
compounds 70 - 72 were synthesized, where the methyl group was substituted by CF3 having a 
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strong –I effect and the MIC values were found to increased over >50 µg/ml against H37Rv 
strain but surprisingly improved against mc2155 strain. Comparing the activity of these sets of 
molecules it can be concluded that the +I groups dominate over the –I groups for their improved 
bactericidal activity against H37Rv strain but a reverse effect was encountered against mc2155 
strain (Table 1). 
 
Table 1: Role of +I and –I effect on antimycobacterial activity. 
MIC (µg/ml)
(H37Rv)
(% Inhibition)
MIC (µg/ml)
(mc26030)
MIC (µg/ml)
(mc2155)
Cytotoxicity
(µg/ml)
N
H
N
H
O
R1
R2
R1 R2 R3
44         H            H                H                nBu(p)
53         H            H                H                nBu(m)
41         H            H                H                allyl(p)
50         H            H                H                allyl(m)
47         H            H                H               prenyl(p)
56         H            H                H               prenyl(m)
46       CH3          H                H                 nBu(p)
55       CH3          H                H                 nBu(m)
43       CH3          H                H                 allyl(p)
52       CH3          H                H                allyl(m)
49       CH3          H                H               prenyl(p)
58       CH3          H                H               prenyl(m)
59         H          CH3              H               prenyl(m)
60         H            H              CH3            prenyl(m)
70       CF3          H                H              prenyl(m)
71         H          CF3              H              prenyl(m)
72         H            H              CF3            prenyl(p)
O R4
>50 (41%)           >100              >200                132.5       
>50 (57%)           50-100           >200                124.1
>50 (84%)            >100             >200                182..4
>50 (73%)              20                 100                150.6
  43.1                      30                  25                 124.7
>50 (79%)              30               >200                168.2
   7.0                     100                100                 130.5
>50 (70%)             >100            >200                175.1
   24.5                    100                 50                   99.2
>50 (68%)             >100           >200                 102.4
>50 (61%)               100               50                 109.6
     5.2                       1               12.5                163.4
    32.2                     nd                50                 175.3
    10.5                     nd              12.5                140.6
>50 (45%)               nd              12.5                  71.4
    40.2                     nd              3.12                135.6
>50 (69%)               nd              6.25                 142.2
R3
R4Comp.
 
 nd = not determined 
 
Correlation between –I & -M vs –I & +M effect and activity: 
To understand the outcome of different substitutions having –I & –M and –I & +M effect, 
we synthesized four sets of molecules. For the first three sets the first aromatic ring is 
substituted with nitro, cyano and carboxylic groups having –I & –M effect, whereas, for 
the fourth set of molecules it is substituted by three different halides (F, Cl and Br) having 
–I & +M effect. Among the others, nitro has the strongest –I & –M effect. Therefore, we 
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selected this one to optimize the aliphatic side chain and its preferred position in the 
second aromatic ring. For this reason we had prepared compounds 42, 45, 48, 51, 54, 57, 
84 and 85 with the nitro at meta, ortho and para positions respectively. The relative 
activity of the compounds 42, 45, 48, 51, 54, 57 showed a clear preference for the prenyl 
chain at meta position as observed previously for compound 58. Only compond 57 of this 
set showed significant effect on three mycobacterium species, the respective MIC value 
were 6 µg/ml, 2 µg/ml and 3.21 µg/ml against H37Rv, mc26030 and mc2155 strains. 
However, a small improvement in activity was observed for para nitro substitution over 
the ortho one. The similar trend was observed for compounds 78, 79, 80 and 86, where 
the first aromatic ring was substituted with a nitrile group (-I & -M) at meta position. 
Their relative activity also probed the preference of prenyl group at meta position, as 
observed for methyl and nitro substitutions. The best activity was found for compound 86 
and the respective MIC values were 9.2 µg/ml and 25 µg/ml against H37Rv and mc2155. 
Similar to the previous sets of molecules same trend was observed for the molecule (90) 
having a carboxy substitution at meta position (Table 2). 
 
Table 2: Role of -I and –M effect on antimycobacterial activity. 
49               H           NO2            H            O-nBu(m)
54               H           NO2            H            O-nBu(p)
51               H           NO2            H            O-allyl(m)
42               H           NO2            H            O-allyl(p)
57               H           NO2            H            O-prenyl(m)
48               H           NO2            H            O-prenyl(p)
84               H           H              NO2          O-prenyl(m)
85             NO2        H                 H            O-prenyl(m)
79               H          CN              H             O-nBu(p)
78               H          CN              H             O-allyl(p)
80               H          CN              H             O-prenyl(p)
86               H          CN              H             O-prenyl(m)
90               H        CO2H            H          O-prenyl(m)
MIC (µg/ml)
(H37Rv)
MIC (µg/ml)
(mc26030)
MIC (µg/ml)
(mc2150)
Cytotoxicity
(µg/ml)
N
H
N
H
O
R4
R1 R3Comp
>50 (75%)         50-100             >200                 92.2
>50 (79%)             50                >200                 97.3
>50 (76%)              5                    50                105.6
    45.5               10-100               100               111.4
.    6.0                     2                   3.21              113.7
>50 (69%)           >100              >200               142.6
>50 (43%)             nd                >200                61.4
>50 (94%)              nd                 100                91.6
>50 (22%)           >100               >200              206.7
>50 (66%)           >100              >200               103.5
.>500 (82%)             5                    50              186.4
 
     9.2                     nd                   25              172.6
.   16.5                    nd                  12.5             132.6
R1
R2
R3
R2 R4
 
nd = not determined 
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 To find out the amendment of activity with –I & +M effect we had prepared another three 
sets of molecules with three different halides 61 – 69. For these three halids (F, Cl and Br) –I 
effect decreases with the increase of atomic number, whereas, the +M effect increases with the 
increase of atomic number. Compounds 61, 62 and 63 with respective fluoro substitution at 
ortho, meta and para positions were found not to be effective against mycobacterium species 
rather than it increases the cytotoxicity level. However, a trivial improvement was observes for 
the meta substitution (62) compared to 61 and 63. For the chloro series (64 - 66) the activity 
trend was found similar to that of fluoro series (Table 3). Nevertheless, the activity profile was 
improved for the chloro series along with an improvement in their cytotoxicity level. For the 
bromo (67 - 69) series the activity was improved to a significant amount compared to their fluoro 
and chloro analogues. Compound 68 showed the best antimycobaterial activity among all other 
halide derivatives and its MIC values were found was found to improved by two folds against  
H37Rv and mc2155 strains. 
 
Table 3: Role of -I and +M effect on antimycobacterial activity. 
F             H              H      
H             F              H           
H             H              F            
Cl            H              H            
H            Cl              H            
H             H             Cl            
Br            H              H
H            Br              H             
H             H             Br
MIC (µg/ml)
(H37Rv)
MIC (µg/ml)
(mc2150)
Cytotoxicity
(µg/ml)
N
H
N
H
O
R1 R3Entry
>50 (68%)            100                 102.8
>50 (89%)             25                    94.0
>50 (45%)             50                    82.4
R1
R2
R3
R2
O
>50 (75%)         50-100                122.3
     48.6                  25                   114.3
>50 (64%)              50                  128.2
>50 (86%)          50-100               135.6
     26.5                 12.5                 148.1
.       38.7                 25                   131.9
63
62
61
66
65
64
69
68
67
 
 
 The comparative activity of these three different halide derivatives clearly showed 
that the inductive effect (I) played a decisive role in enhancing the antimycobaterial 
activity and decreasing of the cytotoxicity level. Similar to the methyl derivatives a small 
favourable steric effect near the urea linkage was also observed for these halide series. 
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2.3 Effect on fatty acid and mycolic acid biosynthesis: 
 To probe the effect of synthesized molecules on mycobacterium fatty acid (FA) 
and mycolic acid (MA) biosynthesis, we have selected eight different compounds from 
each different set. The radio-labeled [1-14C]-acetate was used to determine 
radiometrically their inhibitory effect on different fatty acids and mycolic acid 
biosynthesis. Among the eight molecules compound 47 did not showed any inhibitory 
activity on the biosynthesis of FA and MA as evidenced from the TLC profile (Fig 2), 
whereas, the other compounds 46, 57, 58, 86 and 90 showed their selective inhibitory 
activity on MA biosynthesis. For all these five compounds only the epoxy mycolate 
biosynthesis of M. smegmatis was found to get inhibited but the other two α and α’ 
mycolate biosynthesis were remained almost unaffected. This finding clearly showed the 
importance of the aromatic substitution (first aromatic ring) for inhibition of mycolic acid 
biosynthesis. However, for compound 62 and 71 weak inhibitory activity was observed 
for epoxy mycolate biosynthesis, but interestingly an additional band was observe below 
the epoxy mycolate (Fig 2). 
 
 
FAME = Fatty acid methyl ester; α = α-mycolic acid 
 α’ = α’-mycolic acid; Epoxy = Epoxy-mycolic acid 
 
Fig 2: Inhibition of Fatty acid and Mycolic acid biosynthesis by the synthesized compounds. Compound 
concentrations are 5 times to their MIC value. 
 
 There are two fatty acid synthetases (FAS I and FAS II) present in M. smegmatis 
(mc2155).30 Among these two, FAS I is known to be responsible for the synthesis of C16 to C18 
long fatty acid, whereas, further elongation and functionalization takes place in the FAS II 
module to yield meromycolic acid.31 However, the synthesized molecules did not show any 
inhibitory activity upon fatty acid biosynthesis.  
 
FAME 
α
α′
Epoxy
 
    57      46      58      90      86      47       71     62     DM    Control 
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2.4 Immunomodulatory activity: 
 Mtb is an obligatory aerobic, intracellular pathogen, which has a predilection for 
the lung tissue rich in oxygen supply. Phagocytosis of Mtb by alveolar macrophages is the 
first event in the host-pathogen relationship that decides the outcome of infection. In 
general, the event of phagocytic killing takes place either by toxic reactive oxygen 
intermediates (ROI) or reactive nitrogen intermediates (RNI) or by both. However, RNI is 
known to play a pivotal role during phagocytosis against tubercle bacilli.32  
 In order to determine the production of RNI, we determined the inducible nitric oxide 
synthase (iNOS2) expression in BALB/c derived peritoneal macrophage (representative of all 
tissue macrophages) infected by mc2155 strain, which is primarily responsible for the synthesis 
of RNI from arginine via NADPH mediated pathway.32 A significant increase of iNOS2 
expression in the infected macrophage treated with compound 58 and 86 compared to infected 
macrophage alone evidently indicated their immunoprotective role against infection (Fig 3). 
However, compound 57 showed a little effect on macrophage mediated RNI generation as 
evidenced from the relative iNOS2 expression level for infected and infected but drug treated 
macrophage (Fig 4A). 
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Fig 3: Effect of 58 on iNOS2 expression (A), proinflammatory (IL-12 and IFN-γ) (B-C) and anti-inflammatory (IL-
10) (D) cytokines expression by RT-PCR. Data were represents here from one of three independent experiments 
yielded similar kind of results. Corresponding bars are the mean of the respective densitometry data (mean ± SD). 
*p<0.05; **p<0.01 indicates significant differences compared with indicated respective control. UIM = Uninfected 
macrophage; IM = Infected macrophage; SUT-58 = compound ID for molecule 58. 
 
 Proinflammatory cytokines play a decisive role against mycobacterium infection.33 The 
IFN-γ is known to trigger the macrophage activation for production of RNI via iNOS2, whereas, 
IL-12 get induced during phagocytosis of tubercle bacilli as a natural immunoprotection against 
Mtb infection.34 However, down-regulation of these cytokines is responsible for the disease 
progression. Therefore, we examined the expression level of interferon-γ (IFN-γ) and 
interleukin-12 (IL-12) to validate the effect of the synthesized compounds on proinflammatory 
cytokine oozing during infection. In case of 58 and 86 an increase of IL-12 and IFN-γ expression 
level between infected and infected with treated macrophage clearly demonstrated their potential 
to up-regulate the expression of proinflammatory cytokines in infected macrophage (Fig 3B, 3C 
and Fig 5B, 5C).  Unlike the other two compounds, 57 did not show any positive activity on their 
expression level against infection. 
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Fig 4: Effect of 57 on iNOS2 expression (A), proinflammatory (IL-12 and IFN-γ) (B-C) and anti-inflammatory (IL-
10) (D) cytokines expression by rt-PCR. Data were represents here from one of three independent experiments 
yielded similar kind of results. Corresponding bars are the mean of the respective densitometry data (mean ± SD). 
*p<0.05; **p<0.01 indicates significant differences compared with indicated respective control. UIM = Uninfected 
macrophage; IM = Infected macrophage; SUT-57 = compound ID for molecule 57. 
 
 Interleukin-10 (IL-10) is an anti-inflammatory cytokine and its up-regulation is known to 
be responsible for the tuberculosis progression.35 Therefore, the expression of IL-10 was 
determined in order to find out immunomodulatory activity of the synthesized compounds. In 
case of compound 57, 58, and 86 treated infected macrophage a down-regulation of the IL-10 
was observed compared to the up-regulation of IL-10 level in infected macrophage. 
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Fig 5: Effect of 86 on iNOS2 expression (A), proinflammatory (IL-12 and IFN-γ) (B-C) and anti-
inflammatory (IL-10) (D) cytokines expression by RT-PCR. Data were represents here from one of three 
independent experiments yielded similar kind of results. Corresponding bars are the mean of the respective 
densitometry data (mean ± SD). *p<0.05; **p<0.01 indicates significant differences compared with 
indicated respective control. UIM = Uninfected macrophage; IM = Infected macrophage; SUT-86 = compound ID 
for molecule 86. 
 
 The differential expression level of iNOS2, IFN-γ, IL-12 and IL-10 for the infected and 
treated macrophages compared to uninfected and infected macrophages unambiguously confirms 
the immunomodulatory activity of these synthesized molecules. 
 The cytotoxicity (IC50) of the synthesized compounds against peritoneal macrophages 
was found in the range of 180.9 - 58.1 µg/ml (Table 4) which is almost 16 – 5 higher than the 
isoxyl (Table 5). 
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Table 4:  Cytotoxicity (IC50) against mammalian cell (Peritoneal Macrophage). 
Comp Cytotoxicity 
(µg/ml)  
Comp Cytotoxicity 
(µg/ml)  
Comp Cytotoxicity 
(µg/ml)  
Comp Cytotoxicity 
(µg/ml)  
41 152.6 51 78.4 61 68.2 71 116.7 
42 87.5 52 90.3 62 83.7 72 115.3 
43 122.1 53 121.7 63 87.1 78 96.7 
44 108.9 54 74.3 64 105.6 79 180.9 
45 75.2 55 152.9 65 96.7 80 169.1 
46 125.7 56 141.8 66 115.3 84 58.1 
47 109.5 57 94.1 67 119.4 85 75.2 
48 131.2 58 140.5 68 131.8 86 159.4 
49 81.3 59 160.3 69 140.2 90 120.4 
50 142.5 60 127.6 70 69.4   
 
 
Table 5:  Antimycobacterial activity and cytotoxicity (IC50) values for Isoniazide and Isoxyl. 
Comp MIC (µg/ml) 
H37Rv 
MIC (µg/ml) 
mc26030 
MIC (µg/ml) 
mc2155 
Cytotoxicity 
(µg/ml) HepG2 
Cytotoxicity (µg/ml) 
macrophage 
Isoniazid 0.11 0.05 6.25 >200 >200 
Isoxyl 2.3 nd 25 31.3 12.5 
 
 
3. Conclusion: 
 Unsymmetrical diaryl ureas are shown to have a significant effect against Mtb. The 
SAR study of the synthesized compounds demonstrated the positional preference of 
different functional groups in both of the aromatic rings. For the first aromatic ring ortho 
and meta positions were found to be the preferred one for the groups having +I and –I & -
M effect respectively. The best activity was found for 58 which has the strongest +I effect 
and for 57 with the strongest –I & –M effect than the others. However, compounds having 
–I and –I & +M showed moderate antitubercular activity. On the other hand, for the 
second aromatic ring, best activity was found for the molecules having prenyl group at the 
meta position, whereas, except compound 46, other aliphatic substitutions showed 
moderate activity.  In this series it was found that the substitution of thiourea moiety with 
its bioisostere not only reduces the cytotoxicity by 40 folds (comp. 58 and isoxyl) but also 
can disengage the participation of FMO (Flavin monooxygenase). Moreover, these series 
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of molecules are quite distinctive in the sense of their selective inhibitory activity towards 
mycolic acid biosynthesis.  
 The Mtb is known to suppress the immune response of the host cell during 
infection. Therefore, rejuvenation of the immune response of macrophage has an 
important role to clear the bacterium. Interestingly, molecules 58 and 86 showed a 
significant impact to re-educate the immune response in favour to the host. Therefore, 
these molecules are not only capable to kill the mycobacterium in a direct killing method 
by perturbation of the mycolic acid biosynthesis but also able to clear the mycobacterium 
in a macrophage mediated pathway by upregulation of the proinflammatory and 
downregulation of the anti-inflammatory cytokines.  
 Altogether, these findings have a deep impact on the development of potent 
antimycobacterial molecules with dual killing effect and high selectivity. 
 
4. Experimental:  
4.1 Reagents and instrumentation: 
 All the chemicals were purchased from Sigma–Aldrich, Alfa Aesar and Merck 
Chemicals. Column chromatographic separations were performed using silica gel (100–200 
mesh). Solvents were dried and distilled following standard procedures. TLC was carried out on 
pre-coated plates (Merck silica gel 60, f254), and the spots were visualized with UV light or by 
charring the plates dipped in 10% PMA solution in methanol or 5% H2SO4/vanillin/EtOH. 1H 
NMR (300, 400 MHz) and 13C NMR (75, 100 MHz) spectra were recorded on a Bruker NMR 
spectrometer (δ scale). UV–vis measurements were made using a Perkin Elmer UV–vis 
spectrophotometer (Model Lambda 25). Mass spectra had been recorded using Waters Mass 
Spectrometer (model XevoG2QTof). 
 
4.2 Synthesis of urea derivatives: General method: 
Method A: 3- and 4-Methoxyphenyl isocyanate (individually as per the scheme 1) was 
added drop wise to a stirred solution of the corresponding amine in dichloromethane 
(DCM) and was allowed to stir at room temperature until the completion of reaction 
(checked by TLC). The organic solvent was then evaporated under reduced pressure. 
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Crude residues thus obtained were purified over silica gel column chromatography using 
hexanes and ethyl acetate as eluent. 
Method B: To a stirred solution of p-anisidine in DCM (dry) three different phenyl 
isocyanates were added (individually as per the scheme 2) and the stirring was continued 
at room temperature until the completion of reaction (checked by TLC). The organic 
solvent was then evaporated under reduced pressure. Crude residues thus obtained were 
purified over silica gel column chromatography using hexanes and ethyl acetate. 
 
Demethylation: General method 
Method A: 50% Hydrobromic acid in acetic acid was added to a suspension of the 
methyl ether of urea derivatives dissolved in acetic acid. The clear solution was 
maintained at 70 °C for 12 hrs. After that the reaction mixture was cooled and quenched 
with 10% sodium bicarbonate. Then the organic portion was extracted with ethyl acetate. 
The combined organic layers were washed with water followed by brine solution and then 
dried over sodium sulphate and evaporated to afford the crude product. The crude thus 
obtained was purified by silica gel column chromatography using hexanes and ethyl 
acetate. 
Method B: A solution of the methyl ether of urea derivatives in DCM (dry) was 
maintained at 0-5 °C followed by the addition of 1M solution of Borontribromide (BBr3) 
in DCM. The stirring was continued at room temperature for 4-6 h. After completion of 
the reaction (checked by TLC) it was quenched with 10% sodium bicarbonate and 
extracted with DCM (3X100 ml). Combined organic layers were then washed with water 
followed by brine solution and then dried over sodium sulphate and evaporated to afford 
the crude product. The crude thus obtained was purified by silica gel column 
chromatography using hexanes and ethyl acetate. 
 
General procedure for the Mitsunobu reaction: 
To a solution of alcohol in dry tetrahydrofuran (THF) triphenyl phosphine (PPh3) and 
DIAD were added consecutively and stirred at RT for 15 minutes. Thereafter, the 
corresponding phenolic compound was added slowly to the reaction mixture under 
nitrogen atmosphere and the stirring was continued for 6-8 hours at room temperature. 
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After completion of reaction (by TLC), solvent was evaporated and the crude was 
partitioned between water and ethyl acetate (3X100 ml). The combined organic layers 
were then washed with water followed by brine solution and dried over sodium sulphate. 
The crude thus obtained was purified by column chromatography using a mixture of 
hexanes /ethyl acetate. The purified compounds were dissolved in THF and treated with 
5% aqueous Lithium hydroxide solution (THF/H2O 4:1) for 1 h at room temperature to 
remove the DIAD by-products (as observed from their 1H-NMR). After that the THF was 
removed under reduced pressure and the solid was filtered. The solid thus obtained was 
dried completely and subjected for spectral analysis and bioassay. However, lithium 
hydroxide treatment was not carried out for the Cyano derivatives 78, 79, 80 and 86. 
 
1-(4-(allyloxy)phenyl)-3-phenylurea (41): 
To a solution of Allyl alcohol (0.028 g; 0.48 mmol) in dry THF, TPP (0.149 g; 0.57 mmol) and 
DIAD (0.115 g; 0.57 mmol) were added consecutively and stirred at RT for 15 minutes. 
Thereafter, comp. 21 (0.1 g; 0.44 mmol) was added slowly to the reaction mixture under nitrogen 
atmosphere and the stirring was continued for 8 hours at room temperature. After aqueous 
workup the crude was purified by column chromatography (20% EtOAc in Hexane). Yield: 
59.8%; white solid; m.p. 158-160 oC. 1H NMR (acetone-d6) (300 MHz) – δ 4.38-4.40 (m, 2H), 
5.09 (dd, J = 1.5, 10.3 Hz, 1H), 5.26 (dt, J = 1.8, 17.4 Hz, 1H), 5.88-5.94 (m, 1H), 6.73-6.85 (m, 
3Ar-H), 7.09-7.14 (m, 2Ar-H), 7.29 (dd, J = 1.8, 6.6 Hz, 2Ar-H), 7.37-7.40 (m, 2Ar-H), 7.84 (bs, 
1N-H), 7.94 (brs, 1N-H). 13C NMR (acetone-d6) (75 MHz) - δ 68.7, 114.8, 116.3, 118.4, 184.4, 
120.3, 120.4, 121.8, 128.6, 133.2, 134.1, 140.2, 153.0, 154.2. HRMS (ESI+): m/z calcd for 
C16H17N2O2 [M+H]+: 269.1290; found: 269.1293. 
 
1-(4-(allyloxy)phenyl)-3-(3-nitrophenyl)urea (42): 
To a solution of Allyl alcohol (0.024 g; 0.40 mmol) in dry THF, TPP (0.125 g; 0.48 mmol) and 
DIAD (0.096 g; 0.46 mmol) were added consecutively and stirred at RT for 15 minutes. 
Thereafter, comp. 22 (0.1 g; 0.366 mmol) was added slowly to the reaction mixture under 
nitrogen atmosphere and the stirring was continued for 8 hours at room temperature. After 
aqueous workup the crude was purified by column chromatography (16% EtOAc in Hexane). 
Yield: 52.8%; pale yellow solid; m.p. 182-184 oC. 1H NMR (acetone-d6) (300 MHz) – δ 4.40-
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4.43 (m, 2H), 5.11 (dd, J = 1.5, 10.5 Hz, 1H), 5.28 (dd, J = 1.8, 17.1 Hz, 1H), 5.88-6.01 (m, 1H), 
6.75-6.79 (m, 2Ar-H), 7.31 (dd, J = 2.1, 9.0 Hz, 2Ar-H), 7.41 (t, J = 8.4 Hz, 1Ar-H), 7.67-7.70 
(m, 2Ar-H), 8.00 (brs, 1N-H), 8.50 (brs, 1N-H), 8.51 (t, J = 2.1 Hz, 1Ar-H). 13C NMR (acetone-
d6) (75 MHz) – δ 68.7, 112.6, 114.9, 116.2, 116.4, 120.8, 120.9, 124.1, 124.2, 129.8, 132.6, 
134.1, 141.7, 148.8, 152.9, 154.6. HRMS (ESI+): m/z calcd for C16H16N3O4 [M+H]+: 314.1141 ; 
found: 314.1145. 
 
1-(4-(allyloxy)phenyl)-3-(o-tolyl)urea (43): 
To a solution of Allyl alcohol (0.026 g; 0.45 mmol) in dry THF, TPP (0.141 g; 0.54 mmol) and 
DIAD (0.108 g; 0.54 mmol) were added consecutively and stirred at RT for 15 minutes. 
Thereafter, comp. 23 (0.1 g; 0.41 mmol) was added slowly to the reaction mixture under nitrogen 
atmosphere and the stirring was continued for 8 hours at room temperature. After aqueous 
workup the crude was purified by column chromatography (20% EtOAc in Hexane). Yield: 
61.2%; white solid; m.p. 176-178 oC. 1H NMR (acetone-d6) (300 MHz) – δ 2.13 (s, 3H), 4.39-
4.41 (m, 2H), 5.10 (dd, J = 1.8, 10.5 Hz, 1H), 5.27 (dd, J = 1.8, 17.4 Hz, 1H), 5.89-5.98 (m, 1H), 
6.73-6.83 (m, 3Ar-H), 7.01 (m, 2Ar-H), 7.31 (dd, J = 2.4, 6.9 Hz, 3Ar-H), 7.80-7.83 (m, 1N-H), 
8.14 (brs, 1N-H). 13C NMR (acetone-d6 + CDCl3) (75 MHz) – δ 22.8, 74.9, 120.6, 122.7, 126.6, 
128.0, 129.9, 132.2, 134.1, 135.9, 137.8, 139.2, 142.7, 159.2, 160.6. HRMS (ESI+): m/z calcd 
for C17H19N2O2 [M+H]+: 283.1447; found: 283.1447. 
 
1-(4-butoxyphenyl)-3-phenylurea (44): 
To a solution of n-Butyl alcohol (0.036 g; 0.48 mmol) in dry THF, TPP (0.149 g; 0.57 mmol) 
and DIAD (0.115 g; 0.57 mmol) were added consecutively and stirred at RT for 15 minutes. 
Thereafter, comp. 21 (0.1 g; 0.44 mmol) was added slowly to the reaction mixture under nitrogen 
atmosphere and the stirring was continued for 8 hours at room temperature. After aqueous 
workup the crude was purified by column chromatography (20% EtOAc in Hexane). Yield: 
76.6%; white solid; m.p. 168-170 oC. 1H NMR (acetone-d6) (300 MHz) – δ 0.83 (t, J = 7.5 Hz, 
3H), 1.32-1.39 (m, 2H), 1.57-1.62 (m, 2H), 3.82 (t, J = 6.3, 2H), 6.72 (dd, J = 2.1, 6.6 Hz, 2Ar-
H), 6.83 (t, J = 7.2 Hz, 1Ar-H), 7.13 (t, J = 8.1 Hz, 2Ar-H), 7.28 (dd, J = 2.1, 6.9 Hz, 2Ar-H), 
7.38-7.41 (m, 2Ar-H), 7.80 (brs, 1N-H), 7.91 (brs, 1N-H). 13C NMR (acetone-d6) (75 MHz) - δ 
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13.4, 19.2, 31.5, 67.8, 114.7, 118.6, 120.7, 122.0, 128.8, 133.1, 140.5, 153.0, 155.0. HRMS 
(ESI+): m/z calcd for C17H21N2O2 [M+H]+: 285.1603; found: 285.1601. 
 
1-(4-butoxyphenyl)-3-(3-nitrophenyl)urea (45): 
To a solution of n-Butyl alcohol (0.030 g; 0.40 mmol) in dry THF, TPP (0.125 g; 0.48 mmol) 
and DIAD (0.096 g; 0.48 mmol) were added consecutively and stirred at RT for 15 minutes. 
Thereafter, comp. 22 (0.1 g; 0.37 mmol) was added slowly to the reaction mixture under nitrogen 
atmosphere and the stirring was continued for 8 hours at room temperature. After aqueous 
workup the crude was purified by column chromatography (16% EtOAc in Hexane). Yield: 
48.2%; pale yellow solid; m.p. 196-198 oC. 1H NMR (acetone-d6) (300 MHz) – δ 0.83 (t, J = 7.5 
Hz, 3H), 1.32-1.40 (m, 2H), 1.58-1.63 (m, 2H), 3.83 (t, J = 6.6 Hz, 2H), 6.75 (dd, J = 2.1, 6.9 
Hz, 2Ar-H), 7.30 (d, J = 9.3 Hz, 2Ar-H), 7.41 (t, J = 8.4 Hz, 1Ar-H), 7.67-7.69 (m, 2Ar-H), 7.99 
(brs, 1N-H), 8.45 (brs, 1N-H), 8.51(t, J = 2.4 Hz, 1Ar-H). 13C NMR (d6-DMSO) (100 MHz) – δ 
13.7, 18.7, 30.8, 67.3, 112.0, 114.6, 116.0, 120.5, 124.2, 130.0, 132.1, 141.3, 148.1, 152.6, 154.2. 
HRMS (ESI+): m/z calcd for C17H20N3O4 [M+H]+: 330.1454; found: 330.1459. 
 
1-(4-butoxyphenyl)-3-(o-tolyl)urea (46): 
To a solution of n-Butyl alcohol (0.0336 g; 0.45 mmol) in dry THF, TPP (0.141 g; 0.54 mmol) 
and DIAD (0.108 g; 0.54 mmol) were added consecutively and stirred at RT for 15 minutes. 
Thereafter, comp. 23 (0.1 g; 0.41 mmol) was added slowly to the reaction mixture under nitrogen 
atmosphere and the stirring was continued for 8 hours at room temperature. After aqueous 
workup the crude was purified by column chromatography (20% EtOAc in Hexane). Yield: 
54.6%; off white solid; m.p. 180-182 oC. 1H NMR (acetone-d6) (300 MHz) – δ 0.97 (t, J = 7.2 
Hz, 3H), 1.46-1.51 (m, 2H), 1.72-1.74 ( m, 2H), 2.27 (s, 3H), 3.96 (t, J = 6.0 Hz, 2H), 6.85-6.97 
(m, 3Ar-H), 7.15 (brs, 2Ar-H), 7.44 (d, J = 7.2 Hz, 2Ar-H), 7.96 (d, J = 8.1 Hz, 1N-H), 8.26 (brs, 
1N-H). 13C NMR (d6-DMSO) (100 MHz) – δ 13.7, 17.9, 18.7, 30.8, 67.3, 114.6, 119.7, 120.9, 
122.4, 126.1, 127.2, 130.1, 132.8, 137.6, 152.9, 153.8. HRMS (ESI+): m/z calcd for C18H23N2O2 
[M+H]+: 299.1760; found: 299.1764. 
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1-(4-((3-methylbut-2-en-1-yl)oxy)phenyl)-3-phenylurea (47): 
To a solution of Prenyl alcohol (0.0415 g; 0.48 mmol) in dry THF, TPP (0.149 g; 0.57 mmol) 
and DIAD (0.115 g; 0.57mmol) were added consecutively and stirred at RT for 15 minutes. 
Thereafter, comp. 21 (0.1 g; 0.44 mmol) was added slowly to the reaction mixture under nitrogen 
atmosphere and the stirring was continued for 8 hours at room temperature. After aqueous 
workup the crude was purified by column chromatography (20% EtOAc in Hexane). Yield: 
42.3%; off white solid; m.p. 112-114 oC. 1H NMR (acetone-d6) (300 MHz) – δ 1.61 (d, J = 9.0 
Hz, 6H), 4.37 (d, J = 6.3 Hz, 2H), 5.31 ( t, J = 5.1 Hz, 1H), 6.69-6.74 (m, 2Ar-H), 6.82 (t, J = 7.2 
Hz, 1Ar-H), 7.12 (t, J = 8.1 Hz , 2Ar-H), 7.25-7.29 (m, 2Ar-H) 7.38 (d, J = 7.8 Hz, 2Ar-H), 7.82 
(brs, 1N-H), 7.94 (brs, 1N-H). 13C NMR (acetone-d6) (75 MHz) – δ 17.4, 25.0, 64.8, 114.8, 
118.4, 118.5, 120.4, 120.5, 121.8, 121.9, 128.7, 132.9, 136.6, 140.2, 152.9, 154.6. HRMS 
(ESI+): m/z calcd for C18H21N2O2 [M+H]+: 297.1603; found: 297.1606. 
 
1-(4-((3-methylbut-2-en-1-yl)oxy)phenyl)-3-(3-nitrophenyl)urea (48): 
To a solution of Prenyl alcohol (0.035 g; 0.40 mmol) in dry THF, TPP (0.125 g; 0.48 mmol) and 
DIAD (0.096 g; 0.48 mmol) were added consecutively and stirred at RT for 15 minutes. 
Thereafter, comp. 22 (0.1 g; 0.37 mmol) was added slowly to the reaction mixture under nitrogen 
atmosphere and the stirring was continued for 8 hours at room temperature. After aqueous 
workup the crude was purified by column chromatography (16% EtOAc in Hexane). Yield: 
53.7%; pale brown solid; m.p. 164-166 oC. 1H NMR (acetone-d6) (300 MHz) – δ 1.62 (d, J = 7.8 
Hz, 6H), 4.39 (d, J = 6.6 Hz, 2H), 5.32 (t, J = 1.5 Hz, 1H), 6.75 (dd, J = 1.2, 9 Hz, 2Ar-H), 7.31 
(m, 2Ar-H), 7.41-7.45(m, 1Ar-H), 7.67-7.72 (m, 2Ar-H), 8.01 (brs, 1N-H), 8.46 (brs, 1N-H), 
8.46-8.53 (m, 1Ar-H). 13C NMR (acetone-d6) (75 MHz) – δ 17.3, 24.9, 64.8, 112.6, 114.8, 116.2, 
120.4, 120.9, 124.1, 129.7, 132.3, 136.6, 141.6, 148.8, 152.7, 154.9. HRMS (ESI+): m/z calcd 
for C18H20N3O4 [M+H]+: 342.1454; found: 342.1456. 
 
1-(4-((3-methylbut-2-ene-1-yl)oxy)phenyl)-3-(o-tolyl)urea (49): 
To a solution of Prenyl alcohol (0.039 g; 0.45 mmol) in dry THF, TPP (0.141 g; 0.54 mmol) and 
DIAD (0.108 g; 0.54 mmol) were added consecutively and stirred at RT for 15 minutes. 
Thereafter, comp. 23 (0.1 g; 0.41 mmol) was added slowly to the reaction mixture under nitrogen 
atmosphere and the stirring was continued for 8 hours at room temperature. After aqueous 
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workup the crude was purified by column chromatography (20% EtOAc in Hexane). Yield: 
25.5%; yellow solid; m.p. 52-53 oC; 1H NMR (300 MHz) (CDCl3) – δ 1.74 (s, 3H), 1.80 (s, 3H), 
2.20 (s, 3H), 4.49 (d, J = 6.9 Hz, 2H), 5.46-5.50 (m, 1H), 6.28 (s, 1N-H), 6.40 (s, 1N-H), 6.85-
6.90 (m, 2Ar-H), 7.11 (t, J = 7.5 Hz, 1Ar-H), 7.20-7.26 (m, 4Ar-H), 7.59 (d, J = 7.8 Hz, 1Ar-H). 
13C NMR (100 MHz) (d6-DMSO) – δ 17.9, 18.0, 25.4, 64.4, 114.8, 119.7, 120.2, 120.8, 122.4, 
126.1, 127.2, 130.1, 132.8, 136.7, 137.6, 152.8, 153.5. HRMS (ESI+): m/z calcd for C19H23N2O2 
[M+H]+: 311.1760; found: 311.1757. 
 
1-(3-(allyloxy)phenyl)-3-phenylurea (50): 
To a solution of Allyl alcohol (0.028 g; 0.48 mmol) in dry THF, TPP (0.149 g; 0.57 mmol) and 
DIAD (0.115 g; 0.57 mmol) were added consecutively and stirred at RT for 15 minutes. 
Thereafter, comp. 24 (0.1 g; 0.4381 mmol) was added slowly to the reaction mixture under 
nitrogen atmosphere and the stirring was continued for 8 hours at room temperature. After 
aqueous workup the crude was purified by column chromatography (20% EtOAc in Hexane). 
Yield: 45.2%; off white solid; m.p. 142-144 oC. 1H NMR (acetone-d6) (300 MHz) – δ 4.40-4.43 
(m, 2H), 5.11 (dd, J = 1.5, 10.5 Hz, 1H), 5.29 (dd, J = 1.5, 17.1 Hz, 1H), 5.90-5.93 (m, 1H), 6.41 
(dd, J = 2.4, 8.1 Hz, 1Ar-H), 6.85-6.87 (m, 2Ar-H), 7.00-7.03 (m, 1Ar-H), 7.14 (t, J = 8.4 Hz, 
2Ar-H), 7.22 (t, J = 2.1 Hz, 1Ar-H), 7.40 (d, J = 7.8 Hz, 2Ar-H), 8.01 (brs, 2N-H). 13C NMR 
(acetone-d6) (75 MHz) – δ 68.3, 105.2, 108.2, 111.0, 116.5, 118.5, 122.1, 128.7, 129.4, 133.9, 
140.0, 141.3, 152.7, 159.2. HRMS (ESI+): m/z calcd for C16H17N2O2 [M+H]+: 269.1290; found: 
269.1291. 
 
1-(3-(Allyloxy)phenyl)-3-(3-nitrophenyl)urea (51): 
To a solution of Allyl alcohol (0.024 g; 0.40 mmol) in dry THF, TPP (0.125 g; 0.48 mmol) and 
DIAD (0.096 g; 0.48 mmol) were added consecutively and stirred at RT for 15 minutes. 
Thereafter, comp. 25 (0.1 g; 0.366 mmol) was added slowly to the reaction mixture under 
nitrogen atmosphere and the stirring was continued for 8 hours at room temperature. After 
aqueous workup the crude was purified by column chromatography (16% EtOAc in Hexane). 
Yield: 59.2%; pale yellow solid; m.p. 126-128 oC; 1H NMR (300 MHz) (acetone-d6) – δ 4.56-
4.59 (m, 2H), 5.26 (dd, J = 1.5, 10.8 Hz, 1H), 5.40-5.48 (m, 1H), 6.03-6.16 (m, 1H), 6.64 (dd, J 
= 2.4, 8.4 Hz, 1Ar-H), 7.02-7.05 (m, 1Ar-H), 7.20 (t, J = 8.1 Hz, 1Ar-H), 7.37 (t, J = 2.1 Hz, 
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1Ar-H), 7.57 (t, J = 8.1 Hz, 1Ar-H), 7.81-7.88 (m, 2Ar-H), 8.35 (brs, 1N-H), 8.67 (t, J = 2.1 Hz, 
1N-H, 1Ar-H).  13C NMR (75 MHz) (acetone-d6 + CDCl3) – δ 73.9, 111.1, 114.8, 116.6, 118.2, 
121.3, 122.4, 129.4, 134.9, 138.4, 153.0, 157.4, 162.1, 164.1. HRMS (ESI+): m/z calcd for 
C16H16N3O4 [M+H]+: 314.1141 ; found: 314.1138. 
 
1-(3-(allyloxy)phenyl)-3-(o-tolyl)urea (52): 
To a solution of Allyl alcohol (0.026 g; 0.45 mmol) in dry THF, TPP (0.141 g; 0.54 mmol) and 
DIAD (0.108 g; 0.54 mmol) were added consecutively and stirred at RT for 15 minutes. 
Thereafter, comp. 26 (0.1 g; 0.41 mmol) was added slowly to the reaction mixture under nitrogen 
atmosphere and the stirring was continued for 8 hours at room temperature. After aqueous 
workup the crude was purified by column chromatography (20% EtOAc in Hexane). Yield: 69.4; 
white solid; m.p. 144-146 oC. 1H NMR (acetone-d6) (300 MHz) – δ 2.27 (s, 3H), 4.54-4.56 (m, 
2H), 5.23-5.27 (m, 1H), 5.43 (dd, J = 1.5, 17.1 Hz, 1H), 6.13-6.16 (m, 1H), 6.59 (dd, J = 2.4, 8.4 
Hz, 1Ar-H), 6.97-7.01(m, 2Ar-H), 7.14-7.19 (m, 3Ar-H), 7.37 (t, J = 2.1 Hz, 1Ar-H), 7.53 (brs, 
1N-H), 7.94 (d, J = 8.4 Hz, 1Ar-H), 8.47 (brs, 1N-H). 13C NMR (d6-DMSO) (100 MHz) – δ 
17.9, 68.0, 104.5, 107.8, 110.5, 117.2, 121.1, 122.7, 126.1, 127.5, 129.5, 130.2, 133.7, 137.3, 
141.1, 152.6, 158.6. HRMS (ESI+): m/z calcd for C17H19N2O2 [M+H]+: 283.1446; found: 
283.1451. 
 
1-(3-butoxyphenyl)-3-phenylurea (53): 
To a solution of n-Butyl alcohol (0.036 g; 0.48 mmol) in dry THF, TPP (0.149 g; 0.57 mmol) 
and DIAD (0.115 g; 0.57 mmol) were added consecutively and stirred at RT for 15 minutes. 
Thereafter, comp. 24 (0.1 g; 0.44 mmol) was added slowly to the reaction mixture under nitrogen 
atmosphere and the stirring was continued for 8 hours at room temperature. After aqueous 
workup the crude was purified by column chromatography (20% EtOAc in Hexane). Yield: 
56.8%; off white solid; m.p. 138-140 oC. 1H NMR (acetone-d6) (300 MHz) – δ 0.98 (t, J = 7.2 
Hz, 3H), 1.47-1.54 (m, 2H), 1.73-1.76 (m, 2H), 3.98 (t, J = 6.3 Hz, 2H), 6.57 (dt, J = 0.6, 8.1 Hz, 
1Ar-H), 7.01-0.96 (m, 2Ar-H), 7.16 (t, J = 8.1 Hz, 1Ar-H), 7.25 (t, J = 8.4 Hz, 2Ar-H), 7.35 (t, J 
= 2.1 Hz, 1Ar-H), 7.55 (d, J = 8.4 Hz, 2Ar-H), 8.14 (brs, 2N-H). 13C NMR (acetone-d6) (75 
MHz) – δ 13.2, 19.1, 31.3, 67.3, 105.1, 108.2, 110.7, 118.6, 122.1, 128.7, 129.4, 140.0, 141.3, 
152.6, 159.9. HRMS (ESI+): m/z calcd for C17H21N2O2 [M+H]+: 285.1603; found: 285.1608. 
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1-(3-butoxyphenyl)-3-(3-nitrophenyl)urea (54): 
To a solution of n-Butyl alcohol (0.030 g; 0.40 mmol) in dry THF, TPP (0.125 g; 0.48 mmol) 
and DIAD (0.096 g; 0.48 mmol) were added consecutively and stirred at RT for 15 minutes. 
Thereafter, comp. 25 (0.1 g; 0.37 mmol) was added slowly to the reaction mixture under nitrogen 
atmosphere and the stirring was continued for 8 hours at room temperature. After aqueous 
workup the crude was purified by column chromatography (16% EtOAc in Hexane). Yield: 
68.5%; Pale yellow solid; m.p. 108-110 oC. 1H NMR (CDCl3 + acetone-d6) (300 MHz) – δ 0.95 
(t, J = 7.2 Hz, 3H), 1.41-1.48 (m, 2H), 1.69-1.74 (m, 2H), 3.88 (t, J = 6.6 Hz, 2H), 6.62 (d, J = 
7.5 Hz, 1Ar-H), 6.80 (d, J = 7.8 Hz, 1Ar-H), 6.99 (s, 1Ar-H), 7.15 (t, J = 8.1 Hz, 1Ar-H), 7.36 (t, 
J = 8.4 Hz, 1Ar-H), 7.50 (brs, 1N-H), 7.72 (d, J = 8.1 Hz, 1Ar-H), 7.80-7.85 (m, 1Ar-H), 7.85 
(brs, 1N-H), 8.1 (s, 1Ar-H). 13C NMR (CDCl3) (75 MHz) – δ 13.8, 19.2, 31.3, 67.8, 107.8, 110.6, 
113.2, 114.3, 117.8, 125.5, 129.7, 130.0, 138.5, 139.6, 148.5, 153.4, 160.0 HRMS (ESI+): m/z 
calcd for C17H20N3O4 [M+H]+: 330.1454; found: 330.1457. 
 
1-(3-butoxyphenyl)-3-(o-tolyl)urea (55): 
To a solution of n-Butyl alcohol (0.0336 g; 0.45 mmol) in dry THF, TPP (0.141 g; 0.54 mmol) 
and DIAD (0.108 g; 0.54 mmol) were added consecutively and stirred at RT for 15 minutes. 
Thereafter, comp. 26 (0.1 g; 0.41 mmol) was added slowly to the reaction mixture under nitrogen 
atmosphere and the stirring was continued for 8 hours at room temperature. After aqueous 
workup the crude was purified by column chromatography (20% EtOAc in Hexane). Yield: 
65.8%; white solid; m.p. 120-122 oC. 1H NMR (acetone-d6) (300 MHz) – δ 0.97 (t, J  = 7.5 Hz, 
3H), 1.46-1.54 (m, 2H), 1.72-1.77 (m, 2H), 2.27 (s, 3H), 3.97 (t, J = 6.3 Hz, 2H), 6.56 (dd, J = 
2.4, 8.1 Hz, 1Ar-H), 6.95-6.99 (m, 2Ar-H), 7.12-7.18 (m, 3Ar-H), 7.36 (t, J = 1.8 Hz, 1Ar-H), 
7.53 (brs, 1N-H), 7.94 (d, J = 8.1 Hz, 1Ar-H), 8.45 (brs, 1N-H). 13C NMR (acetone-d6) (75 MHz) 
– δ 13.3, 17.3, 19.1, 31.3, 67.3, 104.9, 108.1, 110.6, 121.7, 123.1, 126.2, 128.1, 129.4, 130.2, 
137.7, 141.5, 152.9, 159.9. HRMS (ESI+): m/z calcd for C18H23N2O2 [M+H]+: 299.1759; found: 
299.1766. 
 
1-(3-((3-methylbut-2-en-1-yl)oxy)phenyl)-3-phenylurea (56): 
To a solution of Prenyl alcohol (0.0415 g; 0.48 mmol) in dry THF, TPP (0.149 g; 0.57 mmol) 
and DIAD (0.115 g; 0.57 mmol) were added consecutively and stirred at RT for 15 minutes. 
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Thereafter, comp. 24 (0.1 g; 0.44 mmol) was added slowly to the reaction mixture under nitrogen 
atmosphere and the stirring was continued for 8 hours at room temperature. After aqueous 
workup the crude was purified by column chromatography (20% EtOAc in Hexane). Yield: 
48.3%; off white solid; m.p. 124-126 oC. 1H NMR (acetone-d6) (300 MHz) – δ 1.60 (d, J = 9.0 
Hz, 6H), 4.40 (d, J = 6.6 Hz, 2H), 5.31-5.34 (m, 1H), 6.43 (dd, J = 1.8, 7.5 Hz, 1Ar-H), 6.82-
6.88 (m, 2Ar-H), 7.02 (t, J = 8.1 Hz, 1Ar-H), 7.11-7.19 (m, 3Ar-H), 7.41 (d, J = 8.7 Hz, 2Ar-H), 
8.0 (brs, 2N-H). 13C NMR (acetone-d6) (75 MHz) – δ 17.4, 25.0, 64.5, 67.5, 105.2, 108.3, 110.8,  
118.6, 120.3, 122.1, 128.7, 129.4, 131.3, 136.8, 140.1, 141.3, 152.7, 159.6. HRMS (ESI+): m/z 
calcd for C18H21N2O2 [M+H]+: 297.1603; found: 297.1606. 
 
1-(3-((3-methylbut-2-en-1-yl)oxy)phenyl)-3-(3-nitrophenyl)urea (57): 
To a solution of Prenyl alcohol (0.035 g; 0.40 mmol) in dry THF, TPP (0.125 g; 0.48 mmol) and 
DIAD (0.096 g; 0.48 mmol) were added consecutively and stirred at RT for 15 minutes. 
Thereafter, comp. 25 (0.1 g; 0.37 mmol) was added slowly to the reaction mixture under nitrogen 
atmosphere and the stirring was continued for 8 hours at room temperature. After aqueous 
workup the crude was purified by column chromatography (16% EtOAc in Hexane). Yield: 
64.1%; yellow solid; m.p. 82-84 oC. 1H NMR (acetone-d6) (300 MHz) – δ 1.63 (d, J = 5.8 Hz, 
6H), 4.41 (d, J = 6.6 Hz, 2H), 5.33 (t, J = 1.2 Hz, 1H), 6.46-6.48 (m, 1Ar-H), 6.88-6.91 (m, 1Ar-
H), 7.05 (t, J = 8.1 Hz, 1Ar-H), 7.18 (t, J = 2.1 Hz, 1Ar-H), 7.43 (t, J = 8.4 Hz, 1Ar-H), 7.68-
7.74 (m, 2Ar-H), 8.19 (brs, 1N-H), 8.52 (s, 1N-H)  8.53 (s, 1Ar-H). 13C NMR (CDCl3) (75 MHz) 
– δ 18.2, 25.8, 64.8, 106.6, 110.0, 112.3, 113.8, 117.2, 119.6, 125.0, 129.6, 138.2, 139.5, 140.4, 
148.6, 152.9, 156.6, 159.6. HRMS (ESI+): m/z calcd for C18H20N3O4 [M+H]+: 342.1454; found: 
342.1455. 
 
1-(3-((3-methylbut-2-en-1-yl)oxy)phenyl)-3-(o-tolyl)urea (58): 
To a solution of Prenyl alcohol (0.039 g; 0.45 mmol) in dry THF, TPP (0.141 g; 0.54 mmol) and 
DIAD (0.108 g; 0.54 mmol) were added consecutively and stirred at RT for 15 minutes. 
Thereafter, comp. 26 (0.1 g; 0.41 mmol) was added slowly to the reaction mixture under nitrogen 
atmosphere and the stirring was continued for 8 hours at room temperature. After aqueous 
workup the crude was purified by column chromatography (20% EtOAc in Hexane). Yield: 
51.3%; off white solid; m.p. 130-132 oC. 1H NMR (acetone-d6) (300 MHz) – δ 1.62 (d, J = 7.8 
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Hz, 6H), 2.13 (s, 3H), 4.39 (d, J = 6.6 Hz, 2H), 5.32 (m, 1H), 6.40 (dd, J = 1.8, 7.5 Hz, 1Ar-H), 
6.82-6.86 (m, 2Ar-H), 6.98-7.04 (m, 3Ar-H), 7.19 (t, J = 2.1 Hz, 1Ar-H), 7.37 (brs, 1N-H), 7.71-
7.81 (m, 1Ar-H), 8.29 (brs, 1N-H). 13C NMR (acetone-d6) (75 MHz) – δ 17.3, 17.4, 25.0, 64.4, 
105.0, 108.3, 110.6, 120.4, 121.7, 123.1, 126.3, 127.9, 129.4, 130.2, 136.8, 137.7, 141.4, 152.8, 
159.6. HRMS (ESI+): m/z calcd for C19H23N2O2 [M+H]+: 311.1760; found: 311.1761. 
 
1-(3-((3-methylbut-2-en-1-yl)oxy)phenyl)-3-(m-tolyl)urea (59): 
To a solution of Prenyl alcohol (0.039 g; 0.45 mmol) in dry THF, TPP (0.141 g; 0.54 mmol) and 
DIAD (0.108 g; 0.54 mmol) were added consecutively and stirred at RT for 15 minutes. 
Thereafter, comp. 27 (0.1 g; 0.41 mmol) was added slowly to the reaction mixture under nitrogen 
atmosphere and the stirring was continued for 8 hours at room temperature. After aqueous 
workup the crude was purified by column chromatography (20% EtOAc in Hexane). Yield: 
62.5%; off white solid; m.p. 106-108 oC. 1H NMR (300 MHz) (CDCl3) – δ 1.72 (s, 3H), 1.79 (s, 
3H), 2.31 (s, 3H), 4.48 (d, J = 6.6 Hz, 2H), 5.45-5.49 (m, 1H), 6.65-6.69 (m, 1Ar-H), 6.76 (d, J = 
4.5 Hz, 2Ar-H), 6.82-6.85 (m, 1Ar-H), 6.92 (d, J = 7.5 Hz, 1Ar-H), 7.04 (t, J = 2.4 Hz, 1Ar-H), 
7.10-7.12 (m, 1Ar-H), 7.16-7.17 (m, 1Ar-H), 7.19-7.22 (m, 2N-H). 13C NMR (125 MHz) 
(CDCl3) – δ 18.2, 21.4, 25.8, 64.7, 106.9, 110.4, 112.8, 118.0, 119.6, 121.6, 124.7, 128.9, 129.7, 
137.9, 138.2, 139.0, 139.4, 154.1, 159.6. HRMS (ESI+): m/z calcd for C19H23N2O2 [M+H]+: 
311.1760; found: 311.1758. 
 
1-(3-((3-methylbut-2-en-1-yl)oxy)phenyl)-3-(p-tolyl)urea (60): 
To a solution of Prenyl alcohol (0.039 g; 0.45 mmol) in dry THF, TPP (0.141 g; 0.54 mmol) and 
DIAD (0.108 g; 0.54 mmol) were added consecutively and stirred at RT for 15 minutes. 
Thereafter, comp. 28 (0.1 g; 0.41 mmol) was added slowly to the reaction mixture under nitrogen 
atmosphere and the stirring was continued for 8 hours at room temperature. After aqueous 
workup the crude was purified by column chromatography (20% EtOAc in Hexane). Yield: 
56.9%; off white solid; m.p. 154-156 oC. 1H NMR (300 MHz) (CDCl3) – δ 1.69 (s, 3H), 1.76 (s, 
3H), 2.27 (s, 3H), 4.42 (d, J = 6.9 Hz, 2H), 5.41-5.47 (m, 1H), 6.60-6.63 (m, 1Ar-H), 6.77 (dd, J 
= 1.8, 8.1 Hz, 1Ar-H), 7.01-7.15 (m, 7Ar-H), 7.26 (s, 1N-H). 13C NMR (100 MHz) (CDCl3) – δ 
18.4, 21.0, 26.0, 65.0, 107.3, 110.6, 113.1, 119.7, 121.8, 129.9, 130.0, 134.1, 135.4, 138.5, 139.6, 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
31 
 
154.2, 155.4, 156.9, 159.8. HRMS (ESI+): m/z calcd for C19H23N2O2 [M+H]+: 311.1760; found: 
311.1759. 
 
1-(2-fluorophenyl)-3-(3-((3-methylbut-2-en-1-yl)oxy)phenyl)urea (61): 
To a solution of Prenyl alcohol (0.0385 g; 0.45 mmol) in dry THF, TPP (0.138 g; 0.53 mmol) 
and DIAD (0.107 g; 0.53 mmol) were added consecutively and stirred at RT for 15 minutes. 
Thereafter, comp. 29 (0.1 g; 0.41 mmol) was added slowly to the reaction mixture under nitrogen 
atmosphere and the stirring was continued for 6 hours at room temperature. After aqueous 
workup the crude was purified by column chromatography (15% EtOAc in Hexane). Yield: 
65.3%; off white solid; m.p. 138-140 oC. 1H NMR (300 MHz) (CDCl3) – δ 1.73 (s, 3H), 1.79 (s, 
3H), 4.50 (d, J = 6.9 Hz, 2H), 5.48 (t, J = 1.5 Hz, 1H), 6.69-6.72 (m, 1Ar-H), 6.83 (bs, 1N-H), 
6.87 (dd, J = 1.8, 7.8 Hz, 1Ar-H), 6.96-7.07 (m, 3Ar-H and 1N-H), 7.09-7.14 (m, 1Ar-H), 7.23 
(t, J = 8.1 Hz, 1Ar-H), 8.10 (dt, J = 1.5, 8.1 Hz, 1Ar-H). 13C NMR (125 MHz) (CDCl3) – δ 18.2, 
25.8, 64.8, 107.5, 111.1, 113.3, 114.9, 119.6, 122.1, 123.8, 124.6, 126.6, 130.0, 152.2, 153.1, 
159.7. HRMS (ESI+): m/z calcd for C18H20FN2O2 [M+H]+: 315.1509; found: 315.1511. 
 
1-(3-fluorophenyl)-3-(3-((3-methylbut-2-en-1-yl)oxy)phenyl)urea (62): 
To a solution of Prenyl alcohol (0.0385 g; 0.45 mmol) in dry THF, TPP (0.138 g; 0.53 mmol) 
and DIAD (0.107 g; 0.53 mmol) were added consecutively and stirred at RT for 15 minutes. 
Thereafter, comp. 30 (0.1 g; 0.41 mmol) was added slowly to the reaction mixture under nitrogen 
atmosphere and the stirring was continued for 6 hours at room temperature. After aqueous 
workup the crude was purified by column chromatography (15% EtOAc in Hexane). Yield: 
59.8%; off white solid; m.p. 116-118 oC. 1H NMR (300 MHz) (CDCl3) – δ 1.71 (s, 3H), 1.77 (s, 
3H), 4.45 (d, J = 6.6 Hz, 2H), 5.43-5.47 (m, 1H), 6.65-6.81 (m, 3Ar-H), 6.96-6.99 (m, 3Ar-H), 
7.14-7.18 (m, 2Ar-H and 2N-H). 13C NMR (125 MHz) (CDCl3) – δ 18.1, 25.8, 64.8, 107.5, 
107.7, 110.3, 110.7, 113.4, 115.6, 119.4, 129.9, 138.3, 138.8, 139.7, 153.9, 159.6, 162.0, 164.0. 
HRMS (ESI+): m/z calcd for C18H20FN2O2 [M+H]+: 315.1509; found: 315.1510. 
 
1-(4-fluorophenyl)-3-(3-((3-methylbut-2-en-1-yl)oxy)phenyl)urea (63): 
To a solution of Prenyl alcohol (0.0385 g; 0.45 mmol) in dry THF, TPP (0.138 g; 0.53 mmol) 
and DIAD (0.107 g; 0.53 mmol) were added consecutively and stirred at RT for 15 minutes. 
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Thereafter, comp. 31 (0.1 g; 0.41 mmol) was added slowly to the reaction mixture under nitrogen 
atmosphere and the stirring was continued for 6 hours at room temperature. After aqueous 
workup the crude was purified by column chromatography (15% EtOAc in Hexane). Yield: 
63.4%; off white solid; m.p. 156-158 oC. 1H NMR (300 MHz) (CDCl3) – δ 1.73 (s, 3H), 1.79 (s, 
3H), 4.50 (d, J = 6.6 Hz, 2H), 5.46-5.51 (m, 1H), 6.59-6.62 (m, 1Ar-H), 6.94-7.02 (m, 2Ar-H), 
7.16 (t, J = 8.1 Hz, 1Ar-H), 7.20 (t, J = 2.4 Hz, 1Ar-H), 7.36-7.40 (m, 2Ar-H), 7.57 (s, 1N-H), 
7.63 (s, 1N-H). 13C NMR (125 MHz) (d6-DMSO) – δ 18.5, 25.9, 64.6, 105.2, 108.4, 111.0, 
115.6, 115.8, 120.5, 129.9, 136.5, 137.3, 141.3, 153.0, 156.6, 156.9, 159.3, 158.8. HRMS 
(ESI+): m/z calcd for C18H20FN2O2 [M+H]+: 315.1509; found: 315.1513. 
 
1-(2-chlorophenyl)-3-(3-((3-methylbut-2-en-1-yl)oxy)phenyl)urea (64): 
To a solution of Prenyl alcohol (0.036 g; 0.42 mmol) in dry THF, TPP (0.130 g; 0.49 mmol) and 
DIAD (0.1 g; 0.49 mmol) were added consecutively and stirred at RT for 15 minutes. Thereafter, 
comp. 32 (0.1 g; 0.38 mmol) was added slowly to the reaction mixture under nitrogen 
atmosphere and the stirring was continued for 6 hours at room temperature. After aqueous 
workup the crude was purified by column chromatography (15% EtOAc in Hexane). Yield: 
67.3%; off white solid; m.p. 122-124 oC. 1H NMR (300 MHz) (CDCl3) – δ 1.74 (s, 3H), 1.79 (s, 
3H), 4.51 (d, J = 6.9 Hz, 2H), 5.46-5.51 (m, 1H), 6.72-6.76 (m, 1Ar-H), 6.78 (s, 1N-H), 6.91 (dd, 
J = 1.2, 7.8 Hz, 1Ar-H), 6.99 (dt, J = 1.5, 7.8 Hz, 1Ar-H), 7.04 (t, J = 2.1 Hz, 1Ar-H), 7.22-7.23 
(m, 1Ar-H), 7.25-7.26 (s, 1N-H), 7.28-7.29 (m, 1Ar-H), 7.33 (dd, J = 1.5, 8.1 Hz, 1Ar-H), 8.19 
(dd, J = 1.5, 8.4 Hz, 1Ar-H). 13C NMR (100 MHz) (CDCl3) – δ 18.2, 25.8, 64.9, 108.0, 111.5, 
113.8, 119.4, 121.8, 123.3, 123.9, 127.7, 129.1, 130.1, 135.1, 138.5, 138.8, 152.9, 159.8. HRMS 
(ESI+): m/z calcd for C18H20ClN2O2 [M+H]+: 331.1213; found: 331.1217. 
 
1-(3-chlorophenyl)-3-(3-((3-methylbut-2-en-1-yl)oxy)phenyl)urea (65): 
To a solution of Prenyl alcohol (0.036 g; 0.42 mmol) in dry THF, TPP (0.130 g; 0.49 mmol) and 
DIAD (0.1 g; 0.49 mmol) were added consecutively and stirred at RT for 15 minutes. Thereafter, 
comp. 33 (0.1 g; 0.38 mmol) was added slowly to the reaction mixture under nitrogen 
atmosphere and the stirring was continued for 6 hours at room temperature. After aqueous 
workup the crude was purified by column chromatography (15% EtOAc in Hexane). Yield: 
73.6%; off white solid; m.p. 126-128 oC. 1H NMR (300 MHz) (CDCl3) – δ 1.73 (s, 3H), 1.79 (s, 
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3H), 4.49 (d, J = 6.6 Hz, 2H), 5.45-5.49 (m, 1H), 6.70-6.73 (m, 2Ar-H), 6.82-6.86 (m, 2Ar-H), 
6.99 (bs, 1N-H), 7.04-7.05 (m, 1Ar-H), 7.20-7.21 (m, 3Ar-H), 7.40 (s, 1N-H). 13C NMR (100 
MHz) (CDCl3) – δ 18.3, 25.9, 64.9, 107.9, 111.0, 113.5, 118.4, 119.4, 120.4, 123.8, 130.1, 134.7, 
138.5, 138.8, 139.3, 153.6, 159.7. HRMS (ESI+): m/z calcd for C18H20ClN2O2 [M+H]+: 
331.1213; found: 331.1215. 
 
1-(4-chlorophenyl)-3-(3-((3-methylbut-2-en-1-yl)oxy)phenyl)urea (66): 
To a solution of Prenyl alcohol (0.036 g; 0.42 mmol) in dry THF, TPP (0.130 g; 0.49 mmol) and 
DIAD (0.1 g; 0.49 mmol) were added consecutively and stirred at RT for 15 minutes. Thereafter, 
comp. 34 (0.1 g; 0.38 mmol) was added slowly to the reaction mixture under nitrogen 
atmosphere and the stirring was continued for 6 hours at room temperature. After aqueous 
workup the crude was purified by column chromatography (15% EtOAc in Hexane). Yield: 
66.4%; off white solid; m.p. 176-178 oC; 1H NMR (300 MHz) (CDCl3) – δ 1.74 (s, 3H), 1.79 (s, 
3H), 4.50 (d, J = 6.9 Hz, 2H), 5.46-5.51 (m, 1H), 6.61-6.65 (m, 1Ar-H), 6.85-6.89 (m, 1Ar-H), 
7.14-7.15 (m, 1Ar-H), 7.18 (s, 1Ar-H), 7.21-7.26 (m, 2Ar-H), 7.35-7.39 (m, 2Ar-H), 7.40 (s, 1N-
H), 7.51 (s, 1N-H). 13C NMR (100 MHz) (Acetone-d6) – δ 17.3, 24.9, 64.4, 105.3, 108.5, 110.7, 
110.8, 119.9, 120.0, 120.3, 126.7, 128.5, 129.3, 136.7, 138.9, 140.9, 152.3, 159.5. HRMS 
(ESI+): m/z calcd for C18H20ClN2O2 [M+H]+: 331.1213; found: 331.1213. 
 
1-(2-bromophenyl)-3-(3-((3-methylbut-2-en-1-yl)oxy)phenyl)urea (67): 
To a solution of Prenyl alcohol (0.031 g; 0.32 mmol) in dry THF, TPP (0.111 g; 0.42 mmol) and 
DIAD (0.0856 g; 0.42 mmol) were added consecutively and stirred at RT for 15 minutes. 
Thereafter, comp. 35 (0.1 g; 0.33 mmol) was added slowly to the reaction mixture under nitrogen 
atmosphere and the stirring was continued for 6 hours at room temperature. After aqueous 
workup the crude was purified by column chromatography (15% EtOAc in Hexane). Yield: 63.1 
%; off white solid; m.p. 78-80 oC. 1H NMR (300 MHz) (Acetone-d6) – δ 1.61 (d, J = 6.3 Hz, 
6H), 4.40 (d, J = 6.3 Hz, 2H), 5.31-5.33 (m, 1H), 6.45 (dd, J = 2.1, 7.8 Hz, 1Ar-H), 6.86 (d, J = 
7.2 Hz, 1Ar-H), 7.00-7.27 (m, 5Ar-H), 7.82 (t, J = 1.8 Hz, 1Ar-H), 8.04 (s, 1N-H), 8.14 (s, 1N-
H). 13C NMR (100 MHz) (Acetone-d6) – δ 15.9, 23.5, 63.0, 103.9, 107.2, 109.4, 115.7, 118.9, 
119.6, 120.6, 123.3, 127.9, 128.9, 135.3, 139.4, 140.2, 150.8, 158.1. HRMS (ESI+): m/z calcd 
for C18H20BrN2O2 [M+H]+: 375.0708; found: 375.0710. 
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1-(3-bromophenyl)-3-(3-((3-methylbut-2-en-1-yl)oxy)phenyl)urea (68): 
To a solution of Prenyl alcohol (0.031 g; 0.36 mmol) in dry THF, TPP (0.111 g; 0.42 mmol) and 
DIAD (0.0856 g; 0.42 mmol) were added consecutively and stirred at RT for 15 minutes. 
Thereafter, comp. 36 (0.1 g; 0.33 mmol) was added slowly to the reaction mixture under nitrogen 
atmosphere and the stirring was continued for 6 hours at room temperature. After aqueous 
workup the crude was purified by column chromatography (15% EtOAc in Hexane). Yield: 
71.2%; off white solid; m.p. 84-86 oC. 1H NMR (400 MHz) (d6-DMSO) – δ 1.72 (s, 3H), 1.75 (s, 
3H), 4.50 (d, J = 6.4 Hz, 2H), 5.41-5.45 (m, 1H), 6.57 (dd, J = 2.4, 8.4 Hz, 1Ar-H), 6.83-6.87 
(m, 1Ar-H), 7.14-7.24 (m, 5Ar-H), 7.85 (t, J = 1.8 Hz, 1Ar-H), 8.71 (s, 1N-H), 8.84 (s, 1N-H). 
13C NMR (100 MHz) (d6-DMSO) – δ 18.5, 25.9, 64.6, 105.3, 108.7, 111.1, 117.5, 120.5, 120.9, 
122.2, 124.8, 130.0, 131.2, 137.4, 141.0, 141.8, 152.7, 159.3. HRMS (ESI+): m/z calcd for 
C18H20BrN2O2 [M+H]+: 375.0708; found: 375.0709. 
 
1-(4-bromophenyl)-3-(3-((3-methylbut-2-en-1-yl)oxy)phenyl)urea (69): 
To a solution of Prenyl alcohol (0.031 g; 0.33 mmol) in dry THF, TPP (0.111 g; 0.42 mmol) and 
DIAD (0.0856 g; 0.42 mmol) were added consecutively and stirred at RT for 15 minutes. 
Thereafter, comp. 37 (0.1 g; 0.33 mmol) was added slowly to the reaction mixture under nitrogen 
atmosphere and the stirring was continued for 6 hours at room temperature. After aqueous 
workup the crude was purified by column chromatography (15% EtOAc in Hexane). Yield: 
62.8%; white solid; m.p. 168-170 oC. 1H NMR (300 MHz) (d6-DMSO + CDCl3) – δ 1.76 (s, 3H), 
1.80 (s, 3H), 4.59 (d, J = 6.6 Hz, 2H), 5.11 (t, J = 6.6 Hz, 1H), 6.16-6.66 (m, 1Ar-H), 7.26-7.45 
(m, 6Ar-H), 7.51 (dd, J = 2.1, 9.0 Hz, 1 Ar-H), 8.20-8.33 (m, 2N-H).  13C NMR (100 MHz) 
(Acetone-d6 + CDCl3) – δ 17.6, 25.1, 65.4, 103.9, 108.5, 111.3, 114.1, 118.6, 119.5, 120.1, 
128.3, 131.1, 132.2, 137.4, 138.1, 139.5, 152.0, 155.0.  HRMS (ESI+): m/z calcd for 
C18H20BrN2O2 [M+H]+: 375.0708; found: 375.0709. 
 
1-(3-((3-methylbut-2-en-1-yl)oxy)phenyl)-3-(2-(trifluoromethyl)phenyl)urea (70): 
To a solution of Prenyl alcohol (0.032 g; 0.37 mmol) in dry THF, TPP (0.115 g; 0.44 mmol) and 
DIAD (0.088 g; 0.44 mmol) were added consecutively and stirred at RT for 15 minutes. 
Thereafter, comp. 38 (0.1 g; 0.34 mmol) was added slowly to the reaction mixture under nitrogen 
atmosphere and the stirring was continued for 8 hours at room temperature. After aqueous 
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workup the crude was purified by column chromatography (18% EtOAc in Hexane). Yield: 
72.5%; off white solid; m.p. 118-120 oC. 1H NMR (300 MHz) (CDCl3) – δ 1.73 (s, 3H), 1.79 (s, 
3H), 4.49 (d, J = 6.9 Hz, 2H), 5.44-5.50 (m, 1H), 6.74 (dd, J = 2.4, 8.4 Hz, 1Ar-H), 6.84-6.87 
(m, 2Ar-H), 7.03 (t, J = 2.1 Hz, 2Ar-H), 7.14-7.24 (m, 2Ar-H), 7.50-7.58 (m, 1Ar-H, 1N-H), 
8.06 (d, J = 8.4 Hz, 1Ar-H). 13C NMR (100 MHz) (d6-DMSO) – δ 18.0, 25.4, 64.1, 104.6, 108.4, 
110.4, 122.6, 123.7, 125.7, 125.9, 129.6, 132.9, 136.3, 136.9, 140.6, 152.4, 158.9. HRMS 
(ESI+): m/z calcd for C19H20F3N2O2 [M+H]+: 365.1477; found: 365.1481. 
 
1-(3-((3-methylbut-2-en-1-yl)oxy)phenyl)-3-(3-(trifluoromethyl)phenyl)urea (71): 
To a solution of Prenyl alcohol (0.032 g; 0.37 mmol) in dry THF, TPP (0.115 g; 0.44 mmol) and 
DIAD (0.088 g; 0.44 mmol) were added consecutively and stirred at RT for 15 minutes. 
Thereafter, comp. 39 (0.1 g; 0.34 mmol) was added slowly to the reaction mixture under nitrogen 
atmosphere and the stirring was continued for 8 hours at room temperature. After aqueous 
workup the crude was purified by column chromatography (18% EtOAc in Hexane). Yield: 
64.5%; off white solid; m.p. 138-140 oC. 1H NMR (300 MHz) (CDCl3) – δ 1.72 (s, 3H), 1.78 (s, 
3H), 4.48 (d, J = 6.9 Hz, 2H), 5.43-5.49 (m, 1H), 6.69-6.73 (m, 1Ar-H), 6.81-6.85 (m, 1Ar-H), 
6.87 (bs, 1N-H), 6.99 (t, J = 2.4 Hz, 1Ar-H), 7.09 (bs, 1N-H), 7.22 (t, J = 8.1 Hz, 1Ar-H), 7.27-
7.30 (m, 1Ar-H), 7.37 (t, J = 7.8 Hz, 1Ar-H), 7.54 (s, 1Ar-H), 7.57 (s, 1Ar-H). 13C NMR (100 
MHz) (CDCl3) – δ 18.3, 26.0, 65.0, 108.1, 111.1, 113.7, 117.0, 119.5, 120.3, 122.1, 123.4, 125.4, 
129.7, 130.2, 138.6, 138.9, 153.8, 159.9. HRMS (ESI+): m/z calcd for C19H20F3N2O2 [M+H]+: 
365.1477; found: 365.1478. 
 
1-(3-((3-methylbut-2-en-1-yl)oxy)phenyl)-3-(4-(trifluoromethyl)phenyl)urea (72): 
To a solution of Prenyl alcohol (0.032 g; 0.37 mmol) in dry THF, TPP (0.115 g; 0.44 mmol) and 
DIAD (0.088 g; 0.44 mmol) were added consecutively and stirred at RT for 15 minutes. 
Thereafter, comp. 40 (0.1 g; 0.34 mmol) was added slowly to the reaction mixture under nitrogen 
atmosphere and the stirring was continued for 8 hours at room temperature. After aqueous 
workup the crude was purified by column chromatography (18% EtOAc in Hexane). Yield: 
69.0%; off white solid; m.p. 154-156 oC. 1H NMR (300 MHz) (CDCl3) – δ 1.72 (s, 3H), 1.78 (s, 
3H), 4.48 (d, J = 6.9 Hz, 2H), 5.43-5.49 (m, 1H), 6.71-6.75 (m, 1Ar-H), 6.77 (s, 1N-H), 6.83-
6.86 (m, 1Ar-H), 6.99 (t, J = 2.1 Hz, 1Ar-H), 7.03 (s, 1N-H), 7.22 (d, J = 8.1 Hz, 1Ar-H), 7.44-
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7.54 (m, 4Ar-H). 13C NMR (100 MHz) (CDCl3) – δ 18.2, 25.8, 64.8, 106.5, 110.0, 112.1, 116.6, 
118.6, 119.6, 123.5, 126.1, 126.1, 129.7, 138.3, 139.6, 142.2, 152.8, 159.6. HRMS (ESI+): m/z 
calcd for C19H20F3N2O2 [M+H]+: 365.1477; found: 365.1479. 
 
1-(4-(allyloxy)phenyl)-3-(3-cyanophenyl)urea (78): 
To a solution of Allyl alcohol (0.025 g; 0.43 mmol) in dry THF, TPP (0.135 g; 0.51 mmol) and 
DIAD (0.104 g; 0.51 mmol) were added consecutively and stirred at RT for 15 minutes. 
Thereafter, comp. 77 (0.1 g; 0.39 mmol) was added slowly to the reaction mixture under nitrogen 
atmosphere and the stirring was continued for 6 hours at room temperature. After aqueous 
workup the crude was purified by column chromatography (20% EtOAc in Hexane). Yield: 
62.7%; off white solid; m.p. 170-172 oC. 1H NMR (acetone-d6) (300 MHz) – δ 4.54-4.57 (m, 
2H), 5.25 (dd, J = 1.8, 10.8 Hz, 1H), 5.39-5.45 (m, 1H), 6.03-6.07 (m, 1H), 6.90-6.93 (m, 2Ar-
H), 7.35-7.38 (m, 1Ar-H), 7.43-7.51 (m, 3Ar-H), 7.72-7.76 (m, 1Ar-H), 8.07 (t, J = 1.8 Hz, 1Ar-
H), 8.10 (s, 1N-H), 8.41 (s, 1N-H). 13C NMR (d6-DMSO) (100 MHz) – δ 68.1, 105.0, 108.3, 
110.9, 111.6, 117.3, 118.8, 120.8, 122.9, 125.3, 129.6, 130.1, 133.7, 140.5, 140.6, 152.3, 158.6. 
HRMS (ESI+): m/z calcd for C17H16N3O2 [M+H]+: 294.1243; found: 294.1241. 
 
1-(4-butoxyphenyl)-3-(3-cyanophenyl)urea(79): 
To a solution of n-Butyl alcohol (0.032 g; 0.43 mmol) in dry THF, TPP (0.135 g; 0.51 mmol) 
and DIAD (0.104 g; 0.51 mmol) were added consecutively and stirred at RT for 15 minutes. 
Thereafter, comp. 77 (0.1 g; 0.39 mmol) was added slowly to the reaction mixture under nitrogen 
atmosphere and the stirring was continued for 6 hours at room temperature. After aqueous 
workup the crude was purified by column chromatography (20% EtOAc in Hexane). Yield: 
66.5%; off white solid; m.p. 164-166 oC. 1H NMR (acetone-d6) (300 MHz) – δ 0.83 (t, J = 7.2 
Hz, 3H), 1.30-1.42 (m, 2H), 1.55-1.65 (m, 2H), 3.83 (t, J = 6.6 Hz, 2H), 6.74 (dd, J = 2.4, 6.9 
Hz, 2Ar-H), 7.22 (td, J = 1.2,7.5 Hz, 1Ar-H), 7.27-7.37 (m, 3Ar-H), 7.60 (qd, J = 0.9, 8.4 Hz, 
1Ar-H), 7.94-7.92 (m, 2Ar-H), 8.24 (brs, 1N-H). 13C NMR (d6-DMSO) (100 MHz) – δ 13.7, 
18.7, 30.7, 67.0, 104.7, 108.2, 110.6, 111.6, 118.8, 120.8, 122.9, 125.3, 129.5, 130.2, 140.4, 
140.6, 152.3, 159.1. HRMS (ESI+): m/z calcd for C18H20N3O2 [M+H]+: 310.1555; found: 
310.1561. 
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1-(3-cyanophenyl)-3-(4-((3-methylbut-2-en-1-yl)oxy)phenyl)urea (80): 
To a solution of Prenyl alcohol (0.0374 g; 0.43 mmol) in dry THF, TPP (0.135 g; 0.51 mmol) 
and DIAD (0.104 g; 0.51 mmol) were added consecutively and stirred at RT for 15 minutes. 
Thereafter, comp. 77 (0.1 g; 0.39 mmol) was added slowly to the reaction mixture under nitrogen 
atmosphere and the stirring was continued for 6 hours at room temperature. After aqueous 
workup the crude was purified by column chromatography (20% EtOAc in Hexane). Yield: 
61.5%; off white solid; m.p. 160-162 oC. 1H NMR (acetone-d6) (300 MHz) – δ 1.76 (d, J = 8.1 
Hz, 6H), 4.53 (d, J = 6.6 Hz, 2H), 5.44-5.49 (m, 1H), 6.89 (dd, J = 2.1, 6.9 Hz, 2Ar-H), 7.35-
7.51 (m, 4Ar-H), 7.72-7.76 (m, 1Ar-H), 8.07-8.10 (t, J = 1.8 Hz, 1Ar-H), 8.10 (s, 1N-H), 8.42 (s, 
1N-H). 13C NMR (acetone-d6 + CDCl3) (75 MHz) – δ 23.3, 31.0, 70.2, 118.7, 121.1, 123.9, 
125.1, 126.9, 127.0, 127.1, 128.2, 130.8, 134.8, 136.4, 142.7, 145.7, 158.6, 160.5. HRMS 
(ESI+): m/z calcd for C19H20N3O2 [M+H]+: 322.1556; found: 322.1559. 
 
1-(3-((3-methylbut-2-en-1-yl)oxy)phenyl)-3-(2-nitrophenyl)urea (84): 
To a solution of Prenyl alcohol (0.0347 g; 0.40 mmol) in dry THF, TPP (0.125 g; 0.48 mmol) 
and DIAD (0.096 g; 0.48 mmol) were added consecutively and stirred at RT for 15 minutes. 
Thereafter, comp. 81 (0.1 g; 0.37 mmol) was added slowly to the reaction mixture under nitrogen 
atmosphere and the stirring was continued for 8 hours at room temperature. After aqueous 
workup the crude was purified by column chromatography (16% EtOAc in Hexane). Yield: 
73.8%; off white solid; m.p. 60-62 oC. 1H NMR (300 MHz) (CDCl3) – δ 1.75 (s, 3H), 1.80 (s, 
3H), 4.53 (d, J = 6.9 Hz, 2H), 5.48-5.52 (m, 1H), 6.77 (d, J = 8.4 Hz, 1Ar-H), 6.85 (brs, 1N-H), 
6.95 (d, J = 8.1 Hz, 1Ar-H), 7.09-7.12 (m, 2Ar-H), 7.28-7.31 (m, 1Ar-H), 7.63 (t, J = 8.4 Hz, 
1Ar-H), 8.19 (d, J = 8.4 Hz, 1Ar-H), 8.67 (d, J = 8.7 Hz, 1Ar-H), 10.02 (brs, 1N-H). 13C NMR 
(100 MHz) (CDCl3 + Acetone- d6) – δ 18.4, 26.1, 65.1, 108.4, 111.9, 114.1, 119.6, 122.0, 122.2, 
126.0, 130.3, 136.1, 136.2, 136.5, 138.4, 138.7, 152.5, 160.0. HRMS (ESI+): m/z calcd for 
C18H20N3O42 [M+H]+: 342.1454; found: 342.1458. 
 
1-(3-((3-methylbut-2-en-1-yl)oxy)phenyl)-3-(4-nitrophenyl)urea (85): 
To a solution of Prenyl alcohol (0.0347 g; 0.40 mmol) in dry THF, TPP (0.125 g; 0.48 mmol) 
and DIAD (0.096 g; 0.48 mmol) were added consecutively and stirred at RT for 15 minutes. 
Thereafter, comp. 82 (0.1 g; 0.37 mmol) was added slowly to the reaction mixture under nitrogen 
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atmosphere and the stirring was continued for 8 hours at room temperature. After aqueous 
workup the crude was purified by column chromatography (16% EtOAc in Hexane). Yield: 
71.5%; yellow liquid. 1H NMR (300 MHz) (CDCl3) - δ 1.73 (s, 3H), 1.79 (s, 3H), 4.48 (d, J = 
6.6 Hz, 2H), 5.43-5.49 (m, 1H), 6.71 (dd, J = 2.1 , 8.4 Hz, 1Ar-H), 6.87 (dd, J = 1.8, 8.1 Hz, 
1Ar-H), 7.00 (t, J = 2.1 Hz, 1Ar-H), 7.16 (brs, 1N-H), 7.23 (t, J = 8.1 Hz, 1Ar-H), 7.49-7.54 (m, 
2Ar-H), 7.55 (brs, 1N-H), 8.11-8.16 (m, 2Ar-H). 13C NMR (100 MHz) (CDCl3) – δ 18.3, 26.0, 
65.1, 108.3, 110.9, 113.6, 118.6, 119.4, 125.4, 130.3, 138.6, 138.9, 142.5, 145.2, 153.1, 159.8. 
HRMS (ESI+): m/z calcd for C18H20N3O42 [M+H]+: 342.1454; found: 342.1456. 
 
1-(3-cyanophenyl)-3-(3-((3-methylbut-2-en-1-yl)oxy)phenyl)urea (86): 
To a solution of Prenyl alcohol (0.0374 g; 0.43 mmol) in dry THF, TPP (0.135 g; 0.51 mmol) 
and DIAD (0.104 g; 0.51 mmol) were added consecutively and stirred at RT for 15 minutes. 
Thereafter, comp. 83 (0.1 g; 0.39 mmol) was added slowly to the reaction mixture under nitrogen 
atmosphere and the stirring was continued for 6 hours at room temperature. After aqueous 
workup the crude was purified by column chromatography (20% EtOAc in Hexane). Yield: 
68.3%; off white solid; m.p. 138-140 oC. 1H NMR (300 MHz) (CDCl3) – δ 1.72 (s, 3H), 1.78 (s, 
3H), 4.47 (d, J = 6.9 Hz, 2H), 5.43-5.49 (m, 1H), 6.71 (dd, J = 2.4, 8.4 Hz, 1Ar-H), 6.83 (dd, J = 
1.2, 7.8 Hz, 1Ar-H), 6.93-6.95 (s, 1N-H), 6.99 (t, J = 2.1 Hz, 1Ar-H), 7.16-7.18 (m, 1Ar-H), 7.22 
(s, 1N-H), 7.28-7.32 (m, 1Ar-H), 7.35-7.38 (m, 1Ar-H), 7.60-7.63 (m, 2Ar-H). 13C NMR (100 
MHz) (d4-MeOH) – δ 18.2, 25.9, 65.8, 107.1, 110.5, 112.6, 113.7, 119.7, 121.2, 122.8, 124.3, 
126.9, 130.6, 131.1, 138.5, 141.3, 141.9, 154.8, 160.8. HRMS (ESI+): m/z calcd for C19H20N3O2 
[M+H]+: 322.1556; found: 322.1560. 
 
3-(3-(3-((3-methylbut-2-en-1-yl)oxy)phenyl)ureido)benzoic acid (90): 
To a solution of Prenyl alcohol (0.066 g; 0.77 mmol) in dry THF, TPP (0.238 g; 0.91 
mmol) and DIAD (0.184 g; 0.91 mmol) were added consecutively and stirred at RT for 15 
minutes. Thereafter, comp. 89 (0.2 g; 0.69 mmol) was added slowly to the reaction 
mixture under nitrogen atmosphere and the stirring was continued for 8 hours at room 
temperature. After aqueous workup the crude was dissolved in THF/water mixture (4:1) 5 
ml and Lithium hydroxide (0.059 g; 1.40 mmol) was added and stirred at RT for 3 hours. 
After that volatiles evaporated and the aqueous diluted with water and extracted with 
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ethylacetate. Aqueous acidified with HCl and the solid filtered dried and purified by 
column chromatography (30% EtOAc in Hexane). Yield: 52.6% (2 steps); off white solid; 
m.p. 180-182 oC. 1H NMR (300 MHz) (CDCl3 + acetone-d6) – δ 1.75 (s, 3H), 1.79 (s, 
3H), 4.52 (d, J = 6.6 Hz, 2H), 5.46-5.51 (m, 1H), 6.57 (dd, J = 1.5, 7.2 Hz, 1Ar-H), 6.94 
(dd, J = 1.2, 7.8 Hz, 1Ar-H), 7.15 (t, J = 8.1 Hz, 1Ar-H), 7.28 (t, J = 2.1 Hz, 1Ar-H), 7.38 
(t, J = 8.1 Hz, 1Ar-H), 7.69-7.72 (m, 1Ar-H), 7.88-7.91 (m, 1Ar-H), 7.96 (bs, 1N-H), 8.00 
(t, J = 1.8 Hz, 1Ar-H), 8.12 (bs, 1N-H). 13C NMR (100 MHz) (d6-Acetone + CD3CN) – δ 
17.9, 25.4, 65.0, 105.9, 109.3, 111.6, 120.2, 120.6, 123.6, 123.9, 129.5, 130.0, 131.6, 
137.8, 140.6, 141.3, 153.1, 160.0, 167.4. HRMS (ESI+): m/z calcd for C19H21N2O4 
[M+H]+: 341.1501; found: 341.1499. 
 
4.3 Drug susceptibility on M. Smegmatis mc2155 strain: 
 M. smegmatis (mc2155) was cultured in Middlebrook 7H9 broth (HiMedia, India) 
supplemented with 10% (v/v) albumin–dextrose complex (HiMedia, India) and 0.03% 
(v/v) Tween80 at 37 °C. For minimum inhibitory concentration (MIC) testing, two fold 
serial dilutions of compounds were prepared in 360 µl in optically clear, round bottom 
96-well plates. An equivalent volume of mid log–phase mc2155 culture (diluted to an 
optical density at 570 nm of 0.01 was added to achieve a final drug concentration range of 
100–0.78 µg/ml in 7H9 broth, with a control. Plates were incubated in ambient air at 37 
°C for 48 hours, at which point MICs were recorded at the lowest concentration of 
compound that prevented visual growth. 
 
4.4 Drug susceptibility on M. tuberculosis mc26030 strain: 
M. tuberculosis mc26030 was grown at 37 °C in Sauton’s medium supplemented with 20 
µg/ml of pantothenic acid. The susceptibility of M. tuberculosis to the various compounds 
was determined as reported previously.36 In brief, Middlebrook 7H10 solid medium 
containing oleic-albumin-dextrose-catalase enrichment (OADC) and 20 µg/ml of 
pantothenic acid were supplemented with increasing concentrations of the chemical 
analogues. Stock solutions at 10 mg/ml were diluted in DMSO. Serial 10-fold dilutions of 
the actively growing culture were plated and incubated at 37 °C for 2-3 weeks. The 
minimal inhibitory concentration (MIC) was defined as the minimum concentration 
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required for inhibiting 99% of the growth. Isoniazid was included as an antitubercular 
drug control.   
 
4.5 Drug susceptibility on M. tuberculosis H37Rv strain (MABA): 
All compounds were evaluated for MIC against M. tuberculosis H37Rv (ATCC 27294) 
using the microplate Alamar Blue assay (MABA) as previously described37 except that 
we used 7H12 media (instead of 7H9 + glycerol + casitone + OADC). In case of 
compounds exhibiting significant background fluorescence we also used luciferase 
reporter strains of M. tuberculosis H37Rv as well as measurement of intracellular 
adenosine triphosphate. Cultures were incubated in 200 µl medium in 96-well plates for 7 
days at 37 oC. Alamar Blue and Tween 80 were added and incubation was continued for 
24 hours at 37 oC. Fluorescence was determined at excitation/emission wavelengths of 
530/590 nm respectively. The MIC was calculated as the lowest concentration effecting a 
reduction in fluorescence (or luminescence) of 90% relative to controls. Control 
compounds were run in each experiment including isoniazid and rifampin. 
 
4.6 Cytotoxicity study: 
HepG2 cell line (human liver cancer cell): 
 Cytotoxicity assays were performed using the HepG2 cell line (HB-8065) obtained 
from the American Type Culture Collection (ATCC, Manassas, VA). Hep G2 cells were 
propagated in ATCC-formulated Eagle's Minimum Essential Medium supplemented with 
10% fetal bovine serum and maintained in a humidified incubator (37 oC, 5% CO2). After 
scrapping the cells with a cell scraper, they were collected by centrifugation (1000 rpm 
for 5 min), resuspended in fresh medium at ~1x106 cells/mL, dispensed into 96-well 
microplates (100 µl/well) and incubated for 24 h at 37 oC before being used for 
cytotoxicity assays. Test compounds were subsequently added at concentrations ranging 
from 400 to 0.2 µg/mL and incubation continued for another 72 h before the cytopathic 
effects of compounds was determined using the MTT Cell Proliferation Assay (ATCC). 
The cytotoxic IC50 defined as the concentration causing 50% reduction in Hep G2 cell 
viability, was obtained from a dose–response curve plotted from percentage activity 
versus log10 concentration. 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
41 
 
 
Peritoneal macrophages (Normal mammalian cell):  
 Cytotoxicity of compounds against peritoneal macrophages was tested by MTT assay 
described earlier. Briefly, murine peritoneal macrophages (1×106 cells/well in 96-well cell 
culture plates, Genetix) were treated with increasing concentrations of compounds ranging from 
0.1 µg/ml to 250 µg/ml were further cultured in RPMI-1640 supplemented with 10% FBS for 
48h. Then 10 µl of MTT (5 mg/ml) was added and incubated for 3 h at 37°C. Then HCl-
isopropanolic solution (0.04M HCl in isopropanol) was added to each well. After 15 min of 
incubation at room temperature, absorbance of solubilized MTT formazan product was 
spectrophotometrically measured at 570 nm. The cytotoxic IC50 defined as the concentration 
causing 50% reduction in cell viability, was obtained from a dose–response curve plotted from 
percentage activity versus log10 concentration. 
 
4.7 Determination of the effects on mycolic acid biosynthesis: 
 M. smegmatis was grown at 37 ºC and at OD600=1 the culture was divided into 10 
fractions and each of them were treated with a different compound at 5 times its MIC. 
Two controls were made, one culture was treated with DMSO (solvent used for drug 
dissolution) and the other one had no treatment (negative control). The treatment lasted 
for 90 minutes and then the cultures were labelled with 1 µCi/ml [1-14C]-acetate.  
 
Analysis of fatty acids and mycolic acids: 
 De novo fatty acid and mycolic acid biosyntheses were followed by labeling 5 ml 
culture aliquots with 1 µCi/ml [1-14C]-acetate (specific activity: 55.3 mCi/mmol; Perkin 
Elmer) for 1h at 37ºC. Fatty acid and mycolic acid methyl esters were extracted from 
samples containing equivalent amounts of bacteria.31 The resulting solution of FAMEs 
(fatty acid methyl ester) and MAMEs (mycolic acid methyl ester) were assayed for 
radioactivity in a Beckman liquid scintillation counter and then subjected to TLC using 
silica gel plates (5735 silica gel 60F254; Merck). Samples were normalized by cpm and 
developed in hexane:ethyl acetate (9:1, v/v). Autoradiograms were produced by overnight 
exposure to Kodak X-Omat AR film to reveal 14C-labelled FAMEs and MAMEs. 
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4.8 Macrophages and mc2155: 
 Murine peritoneal macrophages were isolated by peritoneal lavage from BALB/c 
mice (817/04/ac/CPCSEA) after 5 days prior 4% thioglycolate i.p. as described earlier.38 
Macrophages were cultured in RPMI1640 with 10% FBS (Gibco) and antibiotics (Gibco) 
for 48 hrs prior all experiments.  
 Fresh culture of bacteria (grown upto mid-log phase) was harvested by 
centrifugation at 2,500 g for 15 min. The bacteria were then washed with PBS twice using 
the centrifugal washing method and finally resuspended in PBS at the desired 
concentration for macrophage infection. 
 
4.9 Infection in macrophages and mRNA expression study: 
 Isolated peritoneal macrophages (2×106 cells/ml) were infected with M. smegmatis  
(mc2155 strain) at macrophage-bacteria ratio of 1:10 for 6hrs followed by non-ingested 
bacteria were removed by washing three times with fresh RPMI 1640 media.39 After that, 
synthesized indicated drug molecules (5µg/mL) were added in the culture medium for 
another 6 hrs. Macrophages were collected in Trizol (Invitrogen) followed by mRNA 
isolation according to the manufacturer’s instructions. cDNA were prepared from each 
sample using 1µg of total RNA by cDNA synthesis kit (Thermo Scientific). cDNA from 
each sample was amplified with green TaqDNA Polymerase (Fermetus) in 25 µl reaction 
volume with following conditions: 95 °C for 90 sec, 94 °C for 45 sec, 60 °C for 1 min, 
and 72 °C for 1 min for a total of 40 cycles in Thermal cycler (Applied biosystem). 
Specific primers (Sigma, India) were used for amplification of iNOS2 (forward: 5’-CAG 
AGG ACC CAG AGA CAA GC-3’; reverse 5’-AAG ACC AGA GGC AGC ACA TC-
3’;), IL-12 (forward 5’-CAC GCC TGA AGA AGA TGA CA-3’; reverse 5’-GAC AGA 
GAC GCC ATT CCA CA-3’), IFN-γ (forward 5’- GGA TAT CTG GAG GAA CTG GC-
3’; Reverse 5’- CGA CTC CTT TTC CGC TTC CT -3’), IL-10 (forward 5’-TCA CTC 
TTC ACC TGC TCC AC-3’; reverse 5’- CTA TGC TGC CTG CTC TTA CTC-3’), and 
GAPDH (forward 5’-GAG CCA AAC GGG TCA TCA TC-3’; reverse, 5’-CCT GCT 
TCA CCA CCT TCT TG-3’) to ensure equal cDNA input.34 
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